

PD-AAA-517

40847

PROGRESS REPORT

Cooperative Agreement No. AID/DPE-3005-A-00-3003-00

1 March 1984 - 28 February 1985

Project # 936-3005

**The Population Council
One Dag Hammarskjold Plaza
New York, New York 10017**

June 1985

Population Council Progress Report

Cooperative Agreement No. AID/DPE-3005-A-00-3003-00

1 March 1984 - 28 February 1985

	<u>Page</u>
I. INTRODUCTION AND SUMMARY	v
II. Cooperative Agreement No. AID/DPE-3005-A-00-3003-00	1
A. Progress Reports on Awards and Subcontracts Active During Reporting Period - By Region	2
1. Latin America and the Caribbean	3
Fundacion Santa Fe de Bogota Bogota, Colombia	4
Centro de Pesquisas e Controle das Doencas Materno-Infantis de Campinas (CEMICAMP) Campinas, Sao Paulo, Brazil	5
Academia Mexicana de Investigacion en Demo- grafia Medica Mexico City, Mexico	6
Consejo Nacional de Poblacion y Familia (CONAPOFA) Santo Domingo, Dominican Republic	7
Asociacion Pro-Bienestar de la Familia Ecuatoriana (APROFE) Guayaquil, Ecuador	8
Academia Mexicana de Investigacion en Demo- grafia Medica Mexico City, Mexico	9
Centro de Pesquisas e Controle das Doencas Materno-Infantis de Campinas (CEMICAMP) Campinas, Sao Paulo, Brazil	10
Academia Mexicana de Investigacion en Demo- grafia Medica Mexico City, Mexico	11
2. South and East Asia	12
Mahidol University, Siriraj Hospital Bangkok, Thailand	13
International Centre for Diarrhoeal Disease Research (ICDDR,B) Dhaka, Bangladesh	14

	<u>Page</u>
3. North America	16
University of Michigan Ann Arbor, Michigan, U.S.A.	184.23A 17
B. Population Council In-House Activities and Project Categories	18
1. Contraceptive Development Program	19
Contraceptive Development Program - 1983	20
Professional Staff Association of the LAC/USC Medical Center Los Angeles, California, U.S.A.	CB83.53A/ICCR 22
Professional Staff Association of the LAC/USC Medical Center Los Angeles, California, U.S.A.	CB83.61A/ICCR 23
Centro Nacional de La Familia Santiago, Chile	CB84.01A/ICCR 24
George Washington University Washington, D.C., U.S.A.	CB83.54A/ICCR 25
Professional Staff Association of the LAC/USC Medical Center Los Angeles, California, U.S.A.	CB83.66A/ICCR 26
Professional Staff Association of the LAC/USC Medical Center Los Angeles, California, U.S.A.	CB83.72A/ICCR 27
Urologische Abteilung Landeskrankenanstalten Salzburg, Austria	B84.07A/ICCR 28
Salk Institute for Biological Studies San Diego, California, U.S.A.	B83.79A/ICCR 29
Contraceptive Development Program - 1984	30
University of Helsinki Helsinki, Finland	CB84.30A/ICCR 32
Professional Staff Association of the LAC/USC Medical Center Los Angeles, California, U.S.A.	CB84.32A/ICCR 33
University of California San Francisco General Hospital San Francisco, California, U.S.A.	CB84.41A/ICCR 34
University of Medicine and Dentistry Rutgers Medical School New Brunswick, New Jersey, U.S.A.	CB84.42A/ICCR 35

	<u>Page</u>
Centro Nacional de La Familia Santiago, Chile	CB84.44A/ICCR 36
George Washington University Washington, D.C., U.S.A.	CB84.20A/ICCR 37
George Washington University Washington, D.C., U.S.A.	CB84.25A/ICCR 38
Centro Nacional de La Familia Santiago, Chile	CB85.04A/ICCR 39
Asociacion Dominicana Pro-Bienestar de la Familia Santo Domingo, Dominican Republic	CB84.09A/ICCR 40
Instituto de Tocoginecologia e Patalogia Mamaria Sao Paulo, Brazil	CB84.14A/ICCR 41
Argus Research Laboratories, Inc. Horsham, Pennsylvania	CB84.18A/ICCR 42
Centro Nacional de La Familia Santiago, Chile	CB84.46A/ICCR 43
Florida Institute of Technology Melbourne, Florida, U.S.A.	B84.10A/ICCR 44
Salk Institute for Biological Studies San Diego, California	B84.27A/ICCR 45
Eastern Virginia Medical School Norfolk, Virginia, U.S.A.	B84.35A/ICCR 46
Eastern Virginia Medical School Norfolk, Virginia, U.S.A.	B84.43A/ICCR 47
2. Fundacion Santa Fe de Bogota In-House Costs	48
3. CEMICAMP In-House Costs	49
4. Academia Mexicana de Investigacion en Demografia Medica In-House Costs	50
5. International Centre for Diarrhoeal Disease Research (ICDDR,B) In-House Costs	51
6. Local Office Expenses, Bogota Office	52
7. Pre-Introduction of Advanced Copper-T IUDs	53
8. Design, Implementation and Evaluation of Family Planning Projects in Sub-Saharan Africa	54
9. Management Consulting for Contraceptive Technologies	56

	<u>Page</u>
10. Pre-Introduction of NORPLANT® Contraceptive Subdermal Implants	57
11. Pre-Introduction Evaluation of NORPLANT® Contraceptive Subdermal Implants	59
12. Local Office Expenses, Bogota Office	60
13. <u>Population and Family Planning Programs, 12th Edition (Fact Book)</u>	61
III. UPDATED INFORMATION ON EXPIRED AWARDS (Final substantive reports have been written for AID in previous Progress Reports.)	62
IV. LIST OF TERMINATED AWARDS AND PROJECTS (Reporting Completed)	63
V. FINANCIAL INFORMATION ON AWARDS, SUBCONTRACTS, AND PROJECTS	64

I. Introduction and Summary

This is the second progress report on activities supported under Cooperative Agreement No. DPE-3005-A-00-3003-00. This agreement provides support for a program in family planning services for the period May 17, 1983 through December 31, 1987. This report includes narrative progress reports and financial information for each in-house activity, subaward, and subcontract supported under the agreement during the period March 1, 1984 through February 28, 1985. The progress reports are presented by region and in-house activities (including subawards and subcontracts connected with Council in-house activities) and the summary of activities is divided into interregional activities, regional activities, and country-specific activities. From March 1, 1984 through February 28, 1985, a total of sixty (60) in-house projects and subawards/subcontracts were active.

Interregional Activities

Interregional activities supported by the Cooperative Agreement included contraceptive development, pre-introduction of advanced Copper-T IUDs, management consulting for contraceptive technologies, and pre-introduction of NORPLANT® contraceptive subdermal implants.

In contraceptive development support was continued for projects on levonorgestral subdermal implants, contraceptive vaginal ring, levonorgestral-releasing IUD device, analogs of luteinizing hormone releasing hormone, and inhibin. Support was also provided for projects on gonadotropin surge inhibiting factor and Tolnidamine. In connection with these projects, support was provided under subcontracts and subawards for studies on the ability of LHRH-13 to inhibit ovulation; comparative use-effectiveness of NORPLANT® and NORPLANT®-2 contraceptive implants; the carcinogenicity of estrogen-progestin combinations delivered intravaginally to rabbits; uterine tumors from rabbits given estrogen-progestin combinations intravaginally; NORPLANT® contraceptives and progesterone vaginal rings; use effectiveness and safety of levonorgestral and TCU 380Ag IUDs; fetal toxicity and Teratogenic study in rabbits; the fractionation and purification of inhibin; gonadotropin surge inhibiting factor (GnSIF) in ovarian follicular fluid.

Support was continued for Population Council in-house projects to prepare for international introduction of the advanced Copper-T intrauterine devices, the TCU 380 and TCU 380Ag; to provide management consulting to AID and AID-supported organizations in the development and regulatory approval of contraceptive technologies; and to initiate pre-introductory activities designed to make NORPLANT® contraceptive subdermal implants available on a global basis. In connection with the latter project, support was provided under subawards to institutions in the Dominican Republic, Ecuador, and Brazil to carry out pre-introduction evaluations of NORPLANT® contraceptive subdermal implants in their countries.

Regional Activities

Support was continued for the Council's in-house project for design, implementation and evaluation of family planning projects in Sub-Saharan Africa. Support was also continued for the Council's office in Bogota, Colombia to monitor and provide technical assistance for AID funded population activities in the Andean Region.

Country-Specific Activities

In Bogota, Colombia support was continued for a project being carried out by the Fundacion Santa Fe de Bogota to test the cost and use effectiveness of integrating natural family planning methods into the Ministry of Health comprehensive health delivery systems. Support was provided to the Academia Mexicana de Investigacion en Demografia Medica in Mexico City, Mexico to evaluate the cost-benefit and cost-effectiveness of the IMSS Family Planning Program in relation to a quantified estimate of the perceived benefits over a defined period of time. Support was also provided to the Academia to conduct a seminar on "Population, Health and Family Planning in the Rural areas of Mexico." In Dhaka, Bangladesh, support was provided to the International Centre for Diarrhoeal Disease Research (ICDDR,B) to continue an integrated program of operations research in Bangladesh. In the United States, support was provided to the Center for Population Planning at the University of Michigan to update the Asian Family Planning Program Data File through 1985.

Progress reports on the projects supported under the agreement during this reporting period follow this summary.

II. COOPERATIVE AGREEMENT NO. AID/DPE-3005-A-00-3005-00

**A. PROGRESS REPORTS ON AWARDS AND SUBCONTRACTS ACTIVE
DURING REPORTING PERIOD - BY REGION**

1. LATIN AMERICA AND THE CARIBBEAN

Population Council Award No. 184.07A

To: Fundación Santa Fé de Bogotá,
Bogotá, Colombia

Period: March 1, 1984 to February 28, 1985

Amount: \$72,995

Approved by AID: March 9, 1984

Status: Expired

Purpose: To test the cost and use effectiveness of integrating natural family planning methods into comprehensive health delivery systems.

The objective of this project is to test the cost and use effectiveness of integrating natural family planning methods into the Ministry of Health comprehensive health delivery systems. Two experimental models are being tested, one involving a special NFP trainer devoted exclusively to promotion and training activities in the community and the other employing an MOH auxiliary nurse who upon receiving additional training in NFP methods offers guidance and training in natural methods as part of her/his functions in the regular maternal-child health program.

During the period March 1, 1984 to February 28, 1985, the following activities were completed, 1) the formalization of an agreement with the MOH to develop through the Bogotá sectional health services; 2) contracting of research personnel; 3) design of the service strategy, the management information system and the development of IE&C materials; 4) the design and completion of a baseline sample survey in the experimental and control areas; 5) the training of MOH personnel and community health workers in NFP methods; 6) the community level promotion of all family planning methods including NFP and, 7) the training and follow-up of NFP users. Two technical narrative reports have been submitted to AID describing in detail the progress made and problems encountered during the first year.

In general, the project is on schedule and complying with all the activities programmed. A request has been made to AID to continue the project for another 18 months to permit the follow-up of NFP users and measure the cost and impact of the promotion of NFP methods on the community and health system. The Fundación Santa Fé is also collaborating with the Maternal-Child Health Division of the MOH in preliminary plans to expand NFP services to the rest of the country.

Population Council Award No. 184.09A

To: Centro de Pesquisas e Controle das Doencas Materno-Infantis de Campinas
Campinas, Sao Paulo, Brazil

Period: April 1, 1984 to March 31, 1985

Amount: \$53,028

Approved by AID: April 2, 1984 (a)
November 28, 1984 (b)*

Status: Current

*Approval of revised scope of work
to include NORPLANT^R activities.

Purpose: For continued support of Copper T IUD Training and Evaluation in
Brazil and to conduct a pre-introduction trial of NORPLANT^R
contraceptive subdermal implants.

Contraceptive prevalence surveys conducted in several Brazilian states have shown that contraceptive use in Brazil has been basically limited to surgical sterilization and the oral pill. This project was developed as a result of the need to increase the options of contraceptive methods available to women in Brazil. The project began several years ago with the principal objective of making copper IUDs available to the general public. The proposed strategy was to select leading gynecologists, primarily from teaching hospitals, to participate in an evaluation of the copper IUD. Training in IUD insertion and clinical management was a precondition to providing the IUDs that would be used by each participating physician in the clinical trials. A total of 30,000 IUDs have been distributed during the course of this project to the 28 participating clinics; of this amount 25,826 devices have been inserted.

A number of papers and presentations have been prepared based on the data collected for the study. Data from six clinics were presented at a symposium held at the Congress of the Brazilian Society of Human Reproduction. Findings from a study done in Campinas comparing the Copper-T380 IUD and the Lippes loop were published in Contraception. Campinas data have also been presented at several meetings including the Latin American Association for Research in Human Reproduction (ALIRH). Clinics in Curitiba and Rio de Janeiro have prepared papers accepted for publication in Brazilian journals. In late 1984, the project resulted in the official approval of use of copper IUDs in Brazil. Brazilian companies have already begun to manufacture and distribute different models of copper-bearing IUDs.

In the fall of 1984, AID approval was requested to use unexpended funds from the Copper-T evaluation to support a similar effort to familiarize health professionals with the NORPLANT[®] contraceptive method. A complete description of these activities is included in the summary of Population Council Award 185.02A (continuation of the study entitled "Pre-Introduction Evaluation of NORPLANT[®] Contraceptive Subdermal Implants in Brazil").

Population Council Award No. 184.21A

To: Asociacion Pro-Bienestar de la Familia Ecuatoriana (APROFE)
Guayaquil, Ecuador

Period: December 1, 1984 to November 30, 1986 Amount: \$24,783

Approved by AID: November 13, 1984 Status: Current

Purpose: To carry out a pre-introduction evaluation of NORPLANT^R contraceptive subdermal implants in Ecuador.

The specific objectives of the project are to:

- 1) develop a program for training medical personnel in insertion and removal procedures of NORPLANT^R implants and in counseling of acceptors;
- 2) evaluate acceptability, training and service delivery requirements under local conditions;
- 3) disseminate information about the NORPLANT^R method to government officials, clinicians, family planning leaders, and potential users;
- 4) provide the government with information required to approve NORPLANT^R implants for distribution.

In February, the project began with APROFE's central office contacting the head medical staff in its centers inviting their participation in the project. The project director also traveled to the APROFE center in Cuenca to discuss the project with an investigator who had participated in the earlier experience with NORPLANT[®] implants in Ecuador, to involve him as a local technical advisor in the project and make key contacts with other physicians in the city. Three physicians were trained in Cuenca during the last week in February. Physicians from seven other APROFE centers were trained in Guayaquil in March by an experienced investigator who also participated in the earlier clinical study.

As of April 30, total enrollment at the nine participating centers reached 201. It is estimated that in less than one year, the total proposed enrollment of 2,100 acceptors will be achieved. Enrollment of acceptors is to be divided among the nine participating APROFE centers and several key physicians practicing in the areas where APROFE centers are located.

Population Council Award No. 184.24A

To: Academia Mexicana de Investigacion en Demografia Medica A.C.
Mexico, D.F., Mexico

Period: October 1, 1984 to December 31, 1984 Amount: \$5,700

Approved by AID: October 10, 1984 Status: Terminated

Purpose: To conduct a seminar on "Population, Health and Family planning
in the Rural areas of Mexico."

With an average attendance of 125 persons, a two-day seminar was conducted in Mexico City on 6-7 December 1984, by the Academia Mexicana de Investigación en Demografía Médica, A.C. and the Mexican Social Security Institute (IMSS).

Papers prepared by experts on the following subjects were presented:

- "An estimate of fertility and mortality in the rural areas of the country".
- "Reproductive behavior among social groups in rural areas of Mexico".
- "Availability of contraceptive methods in rural areas of Mexico".
- "Sociodemographic characteristics of female acceptants of surgical methods".
- "Influence of biological factors and social structure on infant mortality in the rural areas of Mexico 1965-1974".
- "'Less and Better' (a rural health program)".
- "Reproductive risk. Conceptual framework".
- "Reproductive risk factors in maternal, fetal and neonatal death".
- "Elaboration of a prediction model of reproductive risks".

A formal publication is being prepared by the IMSS on the seminar and its contents.

Population Council Award No. 185.02A

To: Centro de Pesquisas e Controle das Doencas Materno-Infantis de Campinas,
Campinas, Sao Paulo, Brazil

Period: February 1, 1985 to January 30, 1986 Amount: \$50,000

Approved by AID: January 30, 1985 Status: Current

Purpose: To continue the study entitled "Pre-Introduction Evaluation of
NORPLANT^R Contraceptive Subdermal Implants in Brazil"

In order to accomplish the objectives of this study it is critical to establish a mechanism in Brazil for:

- 1) training of medical personnel in use of the NORPLANT^R method and in counseling of acceptors;
- 2) disseminating information about the method to government officials, clinicians, family planning leaders, and potential users;
- 3) evaluating acceptability and service delivery requirements under different local conditions;
- 4) facilitating governmental approval for distribution.

The pre-introduction evaluation in Brazil was initiated in July 1984 with funding from the Population Crisis Committee. The study, as originally designed, involved seven clinics, geographically distributed throughout the country. Six additional strategically important centers were added almost immediately, when AID funds became available from Award No. 184.09A. An investigators' meeting was held at CEMICAMP, the coordinating institution for the project. The protocol for the study was approved by the Brazilian Drug Regulatory Agency.

Training of the investigating physicians from the original seven centers was accomplished from July to September 1984. Training of physicians from six additional centers continued on through December.

Enrollment of acceptors into the study began as the training was accomplished at each center. As of March 1985, 1,323 women have enrolled.

Current AID funding will allow the project to expand to eighteen centers. A study of NORPLANT[®]-2 covered rods will begin at three centers once approval for the study is received from the local drug regulatory agency. Also, a study of the users perspective related to NORPLANT[®] implants will be conducted involving acceptors at selected centers.

Population Council Award No. 185.07A

To: Academia Mexicana de Investigacion en Demografia Medica, A.C.,
Mexico, D.F., Mexico

Period: January 1, 1985 to July 31, 1985 Amount: \$5,017

Approved by AID: April 1, 1985 Status: Current

Purpose: To cover computer processing costs that were incurred prior to receipt of the microcomputer system purchased under Award No. 184.10A.

On October 4, 1984, AID officially approved the purchase of one IBM XT micro-computer with peripheral equipment and appropriate software, with funds from Award No. 184.10A.

Since the project under the above-mentioned Award was already in progress, and due to the delay in the delivery of the microcomputer, the Academia Mexicana de Investigación en Demografía Médica requested additional funds to cover the costs of the necessary computer processing during the months of October, November and December 1984.

The money was well spent and enabled timely progress of the main project which thus far has resulted in a paper on the preliminary results of the cost-benefit study of the IMSS family planning program, that will be presented by Dr. Aurora Rábago in the IUSSP Conference in Florence, Italy, in June 1985. The paper was prepared by Dr. Rábago, Mr. Jorge Halvas and consultant Dorothy Nortman.

2. SOUTH AND EAST ASIA

Population Council Award No. 184.06A

To: Mahidol University, Siriraj Hospital,
Bangkok, Thailand

Period: May 1, 1984 to April 30, 1985

Amount: \$9,250

Approved by AID: May 17, 1984

Status: Current

Purpose: To conduct laboratory and clinical studies on the use of
NORPLANT^R-2.

This project is aimed at permitting Thai investigators to gain experience with NORPLANT^R-2 subdermal implants in a Thai population. Ten women are to be enrolled for clinical chemistry studies and 90 for general performance evaluation. Recruitment of the subjects for the clinical chemistry studies was completed in July, 1984.

Population Council Subcontract No. CI84.11A

To: International Centre for Diarrhoeal Disease Research (ICDDR,B),
Dhaka, Bangladesh

Period: May 16, 1984 to June 30, 1985 Amount: \$46,392

Approved by AID: May 17, 1984 Status: Current

Purpose: To continue support of an integrated program of operations research
in Bangladesh.

(This report covers both Subcontract No. CI84.11A and the In-House Project in connection with this subcontract.)

Since May 1, 1982 the Population Council has been engaged in developing an integrated program of operations research at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). This work began with comparative analyses of baseline data from the various areas where the ICDDR,B is working on operational problems with the aim of researching the socio-demographic context in which field studies are conducted and achieving an understanding of the operational barriers to program performance. A series of papers have been produced and seminars conducted over the 1984-85 period to incorporate findings and recommendations of these studies into the Bangladesh Five Year Plan and to introduce mechanisms for operations research into the Government health planning process. Emphasis of the project thus shifted from assisting the ICDDR,B in developing its operations research system to transferring ICDDR,B operations research capabilities to the Government of Bangladesh. Activities, by area and technical components were as follows:

Matlab

The major contributions of the Matlab project in 1984-85 has been work on the integration hypothesis and consultation with the Government on the implications of findings for the Five Year Plan. Findings show that simple but effectively implemented health measures provide an adequate base for launching family planning services, but that comprehensive planning of health care is not a prerequisite to family planning success. This finding, together with the finding that mortality declines have been associated with low fertility, has enabled the Government to scale down unrealistic and overly ambitious donor imposed primary health care schemes, and to focus instead on a few simple to introduce technologies with major potential for fertility and mortality impact.

The Matlab MIS system has been introduced into Government service areas with a population of approximately 350,000. The system has been adapted and modified to Government specifications. Collaborative work with the Government has led to a plan for further dissemination of the system. Software development on MIS emphasizes decentralization of processing with a planned shift of the system to a Matlab field station IBM-PCXT as a demonstration of appropriate applications of computing to program management.

MCH-FP Extension

Work on collaborative projects involving the ICDDR,B and the Government of Bangladesh were addressed to developing concepts of research for decision making in the Government system. Field diagnostic studies involving Government officials were communicated to senior officials and a system of feasibility studies was launched to involve senior officials in research planning. Studies executed in this collaborative design resulted in major changes in Bangladesh government policy. The female field staff will be doubled by the hiring of 10,000 additional workers, the supervisory system will be upgraded and changed to incorporate new MIS and decision making concepts, and the scope of domiciliary family planning services will be expanded to include a wider range of methods and MCH technologies.

Work begun in the early period of the integrated program for operations research was addressed to the need for simple to use computer systems for operations research. Over the 1984-85 period systems were adapted to the IBM-PC to facilitate dissemination. A demographic and service monitoring system known as the Sample Registration system is currently being modified into a user-friendly microcomputer version that is potentially applicable to operations research projects elsewhere in Asia.

Modifications of Project Activities within the Reporting Period

The principal modification of the integrated program in operations research has involved adapting ICDDR,B operations research systems to Government needs, introducing systems into the national program and developing a paradigm for organizational change and development for public sector programs. An approach to operations research has been developed for national programs with exceedingly limited implementation capabilities. A paradigm has been developed for operations research that differs from approaches suited to East Asia where program implementation capabilities are relatively well developed.

3. NORTH AMERICA

Population Council Award No. 184.23A

To: University of Michigan,
Ann Arbor, Michigan

Period: October 1, 1984 to December 31, 1986 Amount: \$99,745

Approved by AID: November 2, 1984 Status: Current

Purpose: To conduct a project entitled "Asian Family Planning Program
Performance."

The award for the project stipulates October 1 as the starting date. It was approved by AID and signed by the University in November. The project got started in January, 1985.

The principal investigator (PI) has restarted the quantitative data collection procedures. He has advised the country correspondents of the resumption of the project and the aim to extend the existing data set through 1985. In a few cases, personnel changes have required the identification of new country correspondents. The Correspondent for Fiji is no longer in residence there, but the PI has written to an officer who was in training last Fall at the University of Michigan.

In preparation for continued work, the PI has reviewed the physical data files, checked them against the computer files, and recreated a series of basic raw data to be returned to the country correspondents. The correspondents are asked to check these data against the most recent historical data sets they have, to fill in missing years, and then to extend the data set up through 1984. This has been a fairly labor intensive and time consuming task.

The PI has also been doing a series of small exercises on the existing data to prepare for both the larger data set and more extensive analyses of the data. The computer consultant is preparing a standard routine for the use of regression diagnostics, with which all assistants are gaining full familiarity. This will provide for a more extensive routine check of all inter- and intra-country relationships. It will also assist in identifying the variety of statistical problems and in determining the best procedures for dealing with those problems.

Finally, the PI has been reviewing the most recent theoretical and empirical work in political and organizational analyses to determine how to improve the measures we currently have. Two new works, on local organization (Esman and Uphoff, 1984) and taxation (Organski, 1984) offer useful ideas for which we shall try to develop operational indices for our countries.

**B. POPULATION COUNCIL IN-HOUSE ACTIVITIES
AND PROJECT CATEGORIES**

CONTRACEPTIVE DEVELOPMENT PROGRAM

Population Council In-House Project

Project: Contraceptive Development Program - 1983

Period: May 17, 1983 to May 16, 1984

Amount: \$630,000(a)
\$141,000(b)
(reduced by \$72,689)*

Approved by AID: July 29, 1983(a) Status: Expired
March 14, 1984(b) (Amendment No. 1)

*This funding was initially assigned to Award No. B84.02A/ICCR, which was later cancelled. The \$72,689 was subsequently applied to the 1984 Contraceptive Development Program.

Purpose: To pursue the development of selected approaches to new contraceptive methods.

Subproject: Levonorgestrel subdermal implants (\$209,176): Phase III comparative trials of the ϵ -capsule system (NORPLANTR) and the two-covered-rod system (NORPLANTR-2) are ongoing in 5 countries including three clinics in the U.S. Enrollment is complete except in two of the U.S. clinics. Also ongoing in separate studies are comparisons of levonorgestrel blood levels for the two dosage forms. The performance of the two forms is nearly identical to date and judged to be highly satisfactory. The findings are expected to permit registration of the NORPLANTR-2 system with regulatory agencies.

Subcontracts:

CB83.53A/ICCR Professional Staff Association of the LAC/USC Medical Center

CB83.61A/ICCR Professional Staff Association of the LAC/USC Medical Center

CB84.01A/ICCR Centro Nacional de la Familia

Subproject: Contraceptive vaginal ring (\$129,116): Preparations were made for large-scale Phase III trials of rings made by mechanized manufacture and designed for one-year use. 2,300 rings were manufactured and manufacturing and control procedures developed. These plans were suspended pending additional interpretation of two animal toxicology experiments: one in monkeys and the other in rabbits. At the end of this project, the rabbit experiment was in its second year and the monkeys had been sacrificed.

Subcontract:

CB83.54A/ICCR George Washington University

Subproject: Levonorgestrel-releasing IUD device (\$80,000): Phase III trials comparing the levonorgestrel IUD and the Copper T Model TCu 380Ag are ongoing in 6 countries. Enrollment of subjects is complete except in the U.S. clinic. The pregnancy rates with both devices have been extremely low to date and the continuation rates satisfactory. A study in rabbits to examine the effects of levonorgestrel release in the uterus is ongoing. The study is entering the second year of a scheduled 2 years. The project is considered to be progressing satisfactorily and on schedule.

Subcontract:

CB83.66A/ICCR Professional Staff Association of the LAC USC Medical Center

Subproject: Analogs of luteinizing hormone releasing hormone (LHRH) (\$65,742): Initial trials of the LHRH agonist that we have designated LHRH-13 gave reassurance of high potency as assessed by gonadotropin release following intranasal administration. Trials of effectiveness in inhibiting ovulation using doses based on these dose-finding studies were, however, unsatisfactory in that ovulation was not regularly inhibited. The reliability of the intranasal delivery is being explored. Tests of use of the agonist to depress spermatogenesis are ongoing. Animal studies of an LHRH antagonist revealed side effects that have caused us to investigate other antagonistic analogs. Research on improved dosage forms for delivery of both agonists and antagonists is under way.

Subcontracts:

CB83.72A/ICCR Professional Staff Association of the LAC/USC Medical Center

B84.07A/ICCR Urologische Abteilung Landeskrankenhäuser, Salzburg

Subproject: Inhibin (\$203,277): Small amounts of a peptide with inhibin activity have been isolated in pure form from ram rete testes fluid. Delays have occurred in obtaining more fluid but arrangements for doing so are now believed to be complete.

Subcontracts:

B83.79A/ICCR Saik Institute for Biological Sciences

Subproject: FDA filing assistant (\$11,000): This assistance aided with the filing of two Investigational New Drug Applications, an NDA supplement and three progress reports to the U.S. Food and Drug Administration.

Population Council Subcontract No. CB83.53A/ICCR

To: Professional Staff Association of the LAC/USC Medical Center
Los Angeles, California

Period: July 1, 1983 to June 30, 1984

Amount: \$42,134

Approved by AID: July 29, 1983

Status: Expired

Purpose: To conduct a comparative study on the subdermal implant system of six capsules (NORPLANT^R) and the alternative system consisting of two covered rods (NORPLANT^R-2).

This project is one unit of a multiclinic comparison of the clinical performance of NORPLANT^R and NORPLANT^R-2 implants. The protocol initially called for the enrollment of 210 subjects at this clinic and their continued monitoring over the effective life of the implants. The enrollment was completed in June, 1983. The present contract provided for continued monitoring of the subjects during a one-year period. 142 subjects of this contingent are continuing in the study as of May, 1985.

Population Council Subcontract No. CB83.61A/ICCR

To: Professional Staff Association of the LAC/USC Medical Center,
Los Angeles, California

Period: October 1, 1983 to September 30, 1984 (a) Amount: \$14,000
Extended to March 31, 1985 (b)

Approved by AID: September 30, 1983 (a) Status: Current
August 8, 1984 (b)

Purpose: To conduct a project entitled "Comparative Use-Effectiveness of
NORPLANT^R and NORPLANT^R-2 Contraceptive Implants."

This contract provided for the enrollment of an additional 140 subjects on the Phase 3 clinical study of NORPLANT^R-2. The additional enrollment at this clinic was judged prudent in view of slow enrollment at one of the other U.S. clinics and the need for a large contingent of U.S. subjects to meet probable FDA requirements. Enrollment was completed in May, 1984. In view of the five-year effective life of the implants, the subjects will be followed for several years.

Population Council Subcontract No. CB84.01A/ICCR

To: Centro Nacional de la Familia,
Santiago, Chile

Period: February 1, 1984 to January 31, 1985 Amount: \$31,000

Approved by AID: February 2, 1984 Status: Expired

Purpose: To conduct a project entitled "Comparative Use-Effectiveness of
NORPLANTR and NORPLANTR-2 Contraceptive Implants."

This project is part of a multiclinic comparison of the NORPLANTR and NOR-PLANTR-2 dosage forms. The protocol called for the enrollment of 210 subjects at this site. The enrollment was completed in March, 1984. 184 subjects are continuing in the study as of May, 1985. The study is expected to continue to gather data on comparative performance through the five-year life of the implants.

Population Council Subcontract No. CB83.54A/ICCR

To: George Washington University
Washington, D.C.

Period: July 1, 1983 to June 30, 1984

Amount: \$39,232

Approved by AID: July 29, 1983

Status: Expired

Purpose: To continue work on a study on the carcinogenicity of Estrogen-Progestin Combinations Delivered intravaginally to Rabbits.

This contract provided support for an intermediate stage of a two-year study of the effects in rabbits of an estrogen-progestin combination delivered continuously to the vagina. Earlier difficulties with deaths due to the rabbits consuming their own hair were largely overcome and the study continued as scheduled.

Population Council Subcontract No. CB93.66A/ICCR

To: Professional Staff Association of the LAC/USC Medical Center,
Los Angeles, California

Period: December 1, 1983 to November 30, 1984 Amount: \$47,520

Approved by AID: November 28, 1983 Status: Expired

Purpose: To conduct a project entitled "Comparative Use-Effectiveness and
Safety of Levonorgestrel and TCU 380Ag IUDs."

This project is part of a multiclinic comparison of the levonorgestrel IUD and the Copper T Model TCU 380Ag. The protocol called for 200 subjects to be enrolled on each device at this clinic. 173 subjects have been enrolled to date, and 152 are continuing in the study. The publicity about pelvic inflammatory disease derived from the Dalkon Shield experience has adversely affected acceptance of IUDs, particularly in California.

Population Council Subcontract No. CB83.72A/ICCR

To: Professional Staff Association of the LAC/USC Medical Center
Los Angeles, California

Period: September 1, 1983 to February 29, 1984 Amount: \$13,772
 Extended to October 31, 1984 (b)

Approved by AID: December 12, 1983 (a) Status: Terminated
 August 8, 1984 (b)

Purpose: To conduct project entitled "The Ability of LHRH-13 to Inhibit
 Ovulation."

The study was aimed at determining the dose of LHRH-13 (an LHRH agonist) required to inhibit ovulation and to identify side effects associated with its use. The study was completed in accordance with the protocol. The study showed the need for higher doses than had originally been anticipated.

Population Council Award No. 384.07A/ICCR

To: Urologische Abteilung Landeskrankenanstalten,
Salzburg, Austria

Period: March 1, 1984 to February 28, 1985

Amount: \$8,000

Approved by AID: March 2, 1984

Status: Terminated

Purpose: To conduct a project entitled "Sperm Suppression with LHRH-13
Agonist."

This project aims at determining whether azoospermia can be attained in men by nasal administration of an LHRH agonist. Four prostate cancer subjects have been enrolled in the study and are receiving daily treatment with LHRH-13.

Population Council Award No. B83.79A/ICCR

To: Salk Institute for Biological Studies,
San Diego, California

Period: December 1, 1983 to April 30, 1984

Amount: \$106,666

Approved by AID: February 6, 1984

Status: Expired

Purpose: To conduct a project entitled "Fractionation and Purification of
Inhibin"

This project is directed to the isolation and characterization of inhibin with the expectation that it might be the basis for an acceptable anti-fertility method in the male. Ram rete testis fluid is being used as an inhibin source. A process of isolation and purification has been developed and a small quantity of apparently pure inhibin prepared. Larger amounts must be prepared to allow for amino acid sequencing.

Population Council In-House Project

Project: Contraceptive Development Program - 1984

Period: March 11, 1984 to February 28, 1985

Amount: \$788,000(a)
\$661,000(b)
\$72,689 (c)*

Approved by AID: May 15, 1984(a)
November 21, 1984(b)
November 21, 1984(c)

Status: Current

*This funding was carried over from the 1983 Contraceptive Development Program

Purpose: To pursue the development of selected approaches to new contraceptive methods.

Subproject: Subdermal implants (\$485,514): The Phase III randomized comparison of the six-capsule system (NORPLANTR) with the two-covered-rod system (NORPLANTR-2) is continuing in seven clinics including three in the U.S. Performance characteristics are essentially identical for the two forms and are highly satisfactory. Levonorgestrel blood levels are being investigated in separate studies and show the two dosage forms to yield nearly identical levels. Additional clinical chemistry studies have been reassuring. Present efforts are concentrated on preparing a New Drug Application.

Subcontracts:

CB84.30A/ICCR University of Helsinki
CB84.32A/ICCR Professional Staff Association of the LAC/USC Medical Center
CB84.41A/ICCR University of California, San Francisco
CB84.42A/ICCR Rutgers Medical School
CB84.44A/ICCR Centro Nacional de la Familia

Subproject: Contraceptive vaginal ring (\$187,862): Development activities on the vaginal ring delivering 290 ug/day of levonorgestrel and 180 ug/day of estradiol were halted because of observations of excessive decidual changes in rabbits in a chronic toxicity study and possibly increased atherosclerosis in a two-year study in cynomolgus monkeys. On a body-weight basis, the doses were several times those used in the human. Efforts in the project are now being concentrated on alternative formulations that will retain the control of ovulation and bleeding patterns of the levonorgestrel/estradiol rings while avoiding the problems encountered in the animal experiments, and on testing a progesterone-releasing ring for use in lactating women.

Subcontracts:

CB84.20A/ICCR George Washington University
CB84.25A/ICCR George Washington University
CB85.04A/ICCR Centro Nacional de la Familia

Subproject: Levonorgestrel-releasing intrauterine device (\$88,922): Phase III trials comparing the levonorgestrel IUD with the Copper T Model TCU 380Ag are ongoing in six countries and indicate very satisfactory performance of both devices. Enrollment of subjects in the study is complete except in the U.S. clinic where acceptance has been disappointingly low. The poor acceptance at this clinic is due to adverse publicity about IUDs deriving

largely from the Dalkon Shield experience. A teratology experiment has been completed in rabbits with no evidence of teratologic effects. A study of carcinogenic potential in rabbits is nearing completion.

Subcontracts:

CB84.09A/ICCR Asociacion Dominicana Pro Bienestar de la Familia Inc.

CB84.14A/ICCR Instituto de Tocoginecologia e Patologia Mamaria

CB84.18A/ICCR Argus Research Laboratories Inc.

CB84.46A/ICCR Centro Nacional de la Familia

CB85.04A/ICCR Centro Nacional de la Familia

Subproject: Analogs of luteinizing hormone releasing hormone (\$86,511):

Activities are concentrated on the analog that we have designated LHRH-13. Following findings of less effective inhibition of ovulation than expected based on experience with single-dose administration, an experiment was undertaken using three different modes of nasal delivery. All three gave good and essentially identical response in volunteer subjects. New trials of ovulation inhibition are, therefore, being mounted using higher doses than in the first study. Chronic use of relatively high doses in porphyric patients has indicated both lack of toxicity and ability to block ovulation. Development efforts on an implant delivery mode are under way. It is visualized as having particular pertinence to inhibiting spermatogenesis in men.

Subproject: Inhibin (\$287,400): A small quantity of possibly pure inhibin has been isolated from ram rete testis fluid. First attempts at sequencing did not yield interpretable results. This may mean that it is not yet pure or consists of more than one peptide chain. Fractionation of a 4.5 l batch of rete testis fluid is under way. A gene library from ram testes is being established. When critical parts of the amino acid sequence have been established and synthesized, it will be possible to use antibodies and nucleotides developed from these sequences to search among bacterial colonies carrying genes from the library to find the one carrying the gene for inhibin synthesis. This may permit bacterial production of inhibin.

Subcontracts:

B84.10A/ICCR Florida Institute of Technology

B84.27A/ICCR Salk Institute for Biological Sciences

Subproject: Gonadotropin surge inhibiting factor (\$252,000): This is a factor produced by the ovary that can prevent the surge of gonadotropins regulating ovulation. A first step toward its isolation and characterization has been the successful development of an in vitro assay to guide fractionation steps.

Subcontracts:

B84.35A/ICCR Eastern Virginia Medical School

B84.43A/ICCR Eastern Virginia Medical School

Subproject: Tolnidamine (\$133,480): Tolnidamine is a compound which interferes with the early stages of spermatogenesis. To provide a base for a Phase I clinical trial, a 28-day toxicity study was conducted in male rats. A highly selective effect on the seminiferous tubule without evidence of systemic toxicity was confirmed. In subsequent mating tests, however, conceptions followed by resorptions were observed. Later the males became sterile. These findings are being further evaluated before deciding on human trials.

Population Council Subcontract No. CB84.30A/ICCR

To: University of Helsinki,
Helsinki, Finland

Period: July 1, 1984 to June 30, 1985

Amount: \$15,000

Approved by AID: July 16, 1984

Status: Current

Purpose: To conduct a project entitled "Laboratory and Clinical Studies
on Contraceptive Implants"

The objectives of this contract were to provide for gonadotropin analysis in studies of the endocrinological effects of NORPLANT^R implants and to compare levonorgestrel blood levels in groups of NORPLANT^R and NORPLANT^R-2 users. Both objectives were accomplished and the blood level comparisons are continuing. Recruiting subjects into the blood level study was somewhat slower than expected.

Population Council Subcontract No. CB84.32A/ICCR

To: Professional Staff Association of LAC/USC Medical Center
Los Angeles, California

Period: July 1, 1984 to June 30, 1985 Amount: \$60,081

Approved by AID: August 10, 1984 Status: Current

Purpose: For continued support of a study entitled "Comparative Use-
Effectiveness of NORPLANT^R and NORPLANT^R-2 Contraceptive Implants"

This contract called for continued monitoring of the subjects enrolled earlier in a multiclinic comparison of NORPLANT^R and NORPLANT^R-2 implants, and for enrolling 150 additional subjects. Enrollment was completed in April, 1985. The implant has met with especially enthusiastic reception at this site and enrollment has been rapid. Of the 554 subjects enrolled, 420 are continuing in the study. In view of the five-year effective life of the implants, the subjects will be followed for several years.

Population Council Subcontract No. CB84.41A/ICCR

To: Regent of The University of California, San Francisco General Hospital,
San Francisco, California

Period: November 16, 1984 to June 30, 1985 Amount: \$72,253

Approved by AID: November 21, 1984 Status: Current

Purpose: To continue the project entitled "Comparative Use-Effectiveness of
NORPLANTR and NORPLANTR-2 Contraceptive Implants"

This project is one unit of a multiclinic comparison of the clinical performance of NORPLANTR and NORPLANTR-2 implants. The scheduled enrollment of 250 subjects has been completed. 217 remain active in the study. The study is expected to continue to gather data on comparative performance through the five-year life of the implants.

Population Council Subcontract No. CB84.42A/ICCR

To: University of Medicine and Dentistry-Rutgers Medical School
New Brunswick, New Jersey

Period: November 16, 1984 to November 15, 1985 Amount: \$75,917

Approved by AID: December 13, 1984 Status: Current

Purpose: To continue the project entitled "Comparative Use-Effectiveness
of NORPLANT^R and NORPLANT^R-2 Contraceptive Implants"

This project is one unit of a multiclinic comparison of the clinical performance of NORPLANT^R and NORPLANT^R-2 implants. The protocol calls for the enrollment of 250 subjects at this clinic. As of May, 1985, 181 women had been enrolled and 18 had discontinued. The rate of enrolling women at this clinic has been considerably slower than expected. Recent publicity on the NORPLANT^R method has, however, led to a tripling of the rate.

Population Council Subcontract No. CB84.44A/ICCR

To: Centro Nacional de La Familia,
Santiago, Chile

Period: February 1, 1985 to October 31, 1985 Amount: \$22,813

Approved by AID: December 17, 1984 Status: Current

Purpose: Continuation of the project entitled "Comparative Use-Effectiveness
of NORPLANT^R and NORPLANT^R-2 Contraceptive Implants."

This project is part of a multiclinic comparison of NORPLANT^R and NORPLANT^R-2 dosage forms and is a continuation of work begun under Subcontract CB84.01A/ICCR. The protocol called for the enrollment of 210 subjects at this site. This was accomplished in March, 1984. 184 subjects are continuing in the study as of May, 1985. The study is expected to continue to gather data on comparative performance through the five-year life of the implants.

Population Council Subcontract No. CB84.20A/ICCR

To: George Washington University,
Washington, D.C.

Period: July 1, 1984 to March 31, 1985 (a) Amount: \$29,625
Extended to May 15, 1985 (b)*

Approved by AID: June 11, 1984 Status: Current

*AID approval not required for extension to
May 15, 1985 pursuant to terms of Cooperative
Agreement No. DPE-3005-A-00-3003-00, Section C,
paragraph 2, subparagraph f.

Purpose: To conduct a project entitled "The Carcinogenicity of Estrogen-
Progestin Combinations Delivered Intravaginally to Rabbits."

This contract provided for the completion of a study begun two years earlier aimed at evaluating in rabbits the carcinogenic potential of levonorgestrel and estradiol delivered continuously to the vagina. The animals were sacrificed in accordance with the protocol and tissues examined grossly and microscopically for evidence of pathology. A final report is being prepared by the Pathologist. Tumorous masses consisting of decidual-like cells were found in some animals.

Population Council Subcontract No. CB84.25A/ICCR

To: George Washington University,
Washington, D.C.

Period: July 1, 1984 to June 30, 1985

Amount: \$48,044

Approved by AID: August 8, 1984

Status: Current

Purpose: To conduct a project entitled "A Study of Uterine Tumors from Rabbits given Estrogen-Progestin Combinations Intravaginally."

This project was initiated to gain further understanding of the tumors observed in rabbits dosed continuously with a combination of estrogen and progestin. Histological studies have confirmed that they consist of cells that possess the characteristics of decidual cells. They have not multiplied and grown when transferred to nude mice.

Population Council Subcontract No. CB85.04A/ICCR

To: Centro Nacional de La Familia,
Santiago, Chile

Period: January 1, 1985 to December 31, 1985

Amount: \$42,196

Approved by AID: February 19, 1985

Status: Current

Purpose: To conduct a project entitled "Laboratory and Clinical Studies on NORPLANT^R Contraceptives and Progesterone Vaginal Rings."

This project provides for continued monitoring of NORPLANT^R implant performance and blood levels in long-term users, for completion of a study of effects of NORPLANT^R use on cortisol and for continuation of a clinical trial of progesterone-containing vaginal rings in lactating women. All facets are progressing satisfactorily. The prospective study of effects of NORPLANT^R on serum cortisol has shown the same distribution of cortisol concentrations as in a parallel group of IUD users. The progesterone rings appear sufficiently promising that an expanded study is being planned.

Population Council Subcontract No. CB84.09A/ICCR

To: Asociacion Dominicana Pro Bienestar de la Familia, Inc.,
Santo Domingo, Dominican Republic

Period: March 1, 1984 to February 28, 1985 Amount: \$23,616

Approved by AID: March 23, 1984 Status: Terminated

Purpose: To conduct a project entitled "Comparative Use-Effectiveness and
Safety of Levonorgestrel and TCU 380Ag IUDs."

This project is part of a multiclinic comparison of the levonorgestrel IUD and the Copper T Model TCU 380Ag. The scheduled enrollment of 200 subjects on each device was accomplished in May, 1982. 97 subjects are continuing to use the devices as of May, 1985. This is a higher discontinuation rate than encountered at other clinics, but follows a pattern characteristic of this clinic in trials of several different contraceptive methods.

Population Council Subcontract No. CB84.14A/ICCR

To: Instituto de Tocoginecologia e Patologia Mamaria,
Sao Paulo, Brazil

Period: June 1, 1984 to May 31, 1985

Amount: \$18,000

Approved by AID: May 7, 1985

Status: Current

Purpose: To conduct a study entitled "Comparative Use-Effectiveness and Safety of Levonorgestrel and TCU 380Ag IUD."

This project is part of a multiclinic comparison of the levonorgestrel IUD and the Copper T Model TCU 380Ag. The scheduled enrollment of 200 subjects on each of the devices was completed in January, 1983. 240 women are continuing to use the devices as of May, 1985. The performance of both devices has been highly satisfactory.

Population Council Subcontract No. CB84.18A/ICCR

To: Argus Research Laboratories, Inc.,
Horsham, Pennsylvania

Period: April 15, 1984 to September 14, 1984

Amount: \$26,306

Approved by AID: April 20, 1984

Status: Expired

Purpose: To conduct a study entitled "Fetal Toxicity and Teratogenic Study
in Rabbits."

This was a teratology study on levonorgestrel-releasing devices placed in the uteri of rabbits after implantation of the embryos had occurred. There was no evidence of teratologic effects. A final report has been received and submitted to the U.S. Food and Drug Administration as part of a progress report on the levonorgestrel-releasing IUD.

Population Council Subcontract No. CB84.46A/ICCR

To: Centro Nacional de La Familia,
Santiago, Chile

Period: October 1, 1984 to September 30, 1985

Amount: \$21,000

Approved by AID: December 17, 1984

Status: Current

Purpose: To continue the project "Comparative Use-Effectiveness and
Safety of the Levonorgestrel and TCU 380Ag IUDs."

This project is part of a multiclinic comparison of the levonorgestrel IUD and the Copper T Model TCU 380Ag. One hundred subjects were to be enrolled on each device at this clinic. This goal was attained in March, 1984. 137 women are continuing to use the devices as of May, 1985.

Population Council Award No. B84.10A/ICCR

To: Florida Institute of Technology,
Melbourne, Florida

Period: March 1, 1984 to February 28, 1985

Amount: \$30,340

Approved by AID: March 23, 1984

Status: Expired

Purpose: To conduct a project entitled "Collection of Ram Rete Testis Fluid."

This project is part of an effort to isolate and characterize a material with inhibin activity from rete testis fluid. It provides for collection of the fluid. Some 4.5 l were collected and forwarded to the Salk Institute for Biological Research for isolation of inhibin.

Population Council Award No. B84.27A/ICCR

To: Salk Institute for Biological Studies
San Diego, California

Period: May 1, 1984 to April 30, 1985

Amount: \$257,060

Approved by AID: July 16, 1984

Status: Current

Purpose To continue support of the project entitled "Fractionation and Purification of Inhibin."

This project is directed to the isolation and characterization of inhibin activity with the expectation that it may form the basis for an acceptable antifertility method in the male. Ram rete testis fluid is being used as a source. A 3,000- to 5,000-fold increase in specific activity has been attained and one ng of protein per ml is maximally active in a pituitary cell culture. First attempts at sequencing did not yield interpretable results which may mean that it is not pure or that it consists of more than one peptide chain. Fractionation of a 4.5 l batch of rete testis fluid is under way.

Population Council Award No. B84.35A/ICCR

To: Eastern Virginia Medical School
Norfolk, Virginia

Period: September 1, 1984 to December 31, 1984 (a) Amount: \$83,472
Extended to August 31, 1985 (b)

Approved by AID: August 29, 1984 (a) Status: Current
April 23, 1985 (b)

Purpose: To conduct a project entitled "Gonadotropin Surge Inhibiting Factor
(GnSIF) in Ovarian Follicular Fluid"

This project aims at the isolation and characterization of the materials produced by the ovaries of humans and several other species that prevent the surge of LH and FSH that follows a bolus of GnRH or estradiol. It is expected that materials with this activity may be useful as antifertility agents.

Initial work has been directed toward the development of a facile in vitro assay that can be used to guide the isolation procedures. An assay system has been achieved which is responsive to GnRH and inhibited by some of the fractions into which follicular fluid has been divided.

Population Council Award No. B84.43A/ICCR

To: Eastern Virginia Medical School
Norfolk, Virginia

Period: January 1, 1985 to August 31, 1985 Amount: \$150,163

Approved by AID: February 13, 1985 Status: Current

Purpose: To continue support of the project entitled "Gonadotropin Surge Inhibiting Factor (GnSIF) in Ovarian Follicular Fluid."

This award supplements Award No. B84.35A/ICCR, in support of initial efforts to achieve the isolation and characterization of substances produced by the ovaries of several species. These substances are effective in preventing the surge of LH and FSH that follows administration of a bolus of GnRH or estradiol. Substances having this type of activity are expected to be useful as antifertility agents.

Attention has initially been given to developing an in vitro assay to guide isolation procedures. An assay system has been achieved which is responsive to GnRH and inhibited by some of the fractions into which follicular fluid has been divided.

Population Council In-House Project

Project: Fundación Santa Fé de Bogotá In-House Costs

Period: January 1, 1984 to December 31, 1984

Amount: \$14,194

Approved by AID: March 9, 1984

Status: Terminated

Purpose: To cover in-house costs in connection with Award No. 184.07A
to Fundación Santa Fé de Bogotá, Bogotá, Colombia

The objective of the Fundación Santa Fé de Bogotá project was to test the cost and use effectiveness of integrating natural family planning methods into comprehensive health delivery systems. The activities of the Council staff in support of this project during 1984 included a) preparation of the final technical proposal; b) technical assistance in the preparation of workplans, sample baseline survey design and data processing as well as the design of the service strategy, management information system and the development of IE&C materials; c) monitoring of field implementation and, d) the preparation of two technical narrative reports for AID.

Approximately 20% of the Bogota office representative's time was devoted to the development of this project. The progress made to date as well as problems encountered are described in greater detail in the reports submitted to AID and the Colombian National Planning Agency covering the periods 1 March - 31 July 1984 and 1 August - 31 December 1984.

Nevertheless, the service and evaluation components have been established and are now functioning in a coherent fashion with the collaboration of local public health authorities. The request for the continuation of this project for 18 months to permit the follow-up of NFP users and measure the cost and impact of the promotion of NFP methods on the community has been made to AID. The Council has received a request for assistance from the Ministry of Health of Colombia to adapt and extend this NFP model to the rest of the country.

Population Council In-House Project

Project: CEMICAMP In-House Costs

Period: April 1, 1984 to March 31, 1985

Amount: \$14,758

Approved by AID: April 2, 1984

Status: Current

Purpose: To cover in-house costs in connection with Award No. 184.09A to Centro de Pesquisas e Controle das Doencas Materno-Infantis de Campinas (CEMICAMP).

In addition to the activities outlined under Population Council Award No. 184.094A (see report for this award), Dr. Anibal Faundes, the Population Council Senior Associate in Brazil, continued to provide technical assistance for the coordination and evaluation of all aspects of the project, including the training in IUD insertions, training in the NORPLANT^R implant system, supervision and collaboration in the preparation of substantive reports on activities and papers on research findings.

Population Council In-House Project

Project: Academia Mexicana de Investigacion en Demografia Medica, A.C.
In-House Costs

Period: March 1, 1984 to July 31, 1985 Amount: \$13,428

Approved by AID: April 20, 1984 Status: Current

Purpose: To cover in-house costs in connection with Award No. I84.10A
to the Academia Mexican de Investigacion en Demografia Medica,A.C.

This project covers three consultancies by Ms. Dorothy Nortman - March 1984; September 1984, and April 1985 - to provide technical assistance in the review and evaluation of procedures, methodology and preliminary results of the Mexican Social Security Institute (IMSS) cost-benefit analysis of its family planning program.

As part of her second consultant assignment, and at the request of the Mexican Demographic Society, Ms. Nortman presented a seminar on cost-benefit analysis of family planning programs with the attendance of staff from El Colegio de México, IMSS, Ministry of Health, and other organizations.

The final product of the three consultancies is a paper on the preliminary results of the cost-benefit study of the IMSS family planning program, that will be presented by Dr. Aurora Rábago at the IUSSP Conference in Florence, Italy, in June 1985.

Population Council In-House Project

Project: International Centre for Diarrhoeal Disease Research, Bangladesh
(ICDDR,B) In-house Costs

Period: May 16, 1984 to June 30, 1985 Amount: \$117,502

Approved by AID: May 17, 1984 Status: Current

Purpose: To cover in-house costs in connection with Population Council
Subcontract No. CI84.11A with the International Centre for
Diarrhoeal Disease Research, Bangladesh.

See report for Subcontract No. CI84.11A.

Population Council In-House Project

Project: Local Office Expenses,
Bogotá, Colombia

Period: May 17, 1983 to April 30, 1984

Amount: \$30,000 (a)
reduced by
\$ 6,546 (b)*

Approved by AID: August 2, 1983 (a)
February 12, 1985 (b)*

Status: Terminated

*\$6,546 in unexpended funds was added to the in-house project for support of the Bogotá Office for the period May 1, 1984 to April 30, 1985.

Purpose: To monitor and provide technical assistance to AID-funded population activities in the Andean Region.

AID funding for the period May 17, 1983 to April 30, 1984 partially covered PC / Bogotá expenditures incurred in the maintenance of the office such as rent and supplies, local staff support, and computer time. Council staff was funded through specific AID sponsored projects as well as from other sources. The activities of the staff assigned to this office included, a) monitoring of on-going projects; b) assisting in the preparation of work plus for the implementation of continuing activities; c) provision of technical assistance and, d) preparation of technical and financial reports for supported projects.

Major projects in Colombia during 1983-1984 were the PROFAMILIA project, Community Distribution of Contraceptives in Rural Areas, which included the provision of family planning services, analysis of major survey data and a study of unmet needs; the Fundación Santa Fé natural family planning project, the CCRP translation and publication program and the CCRP directed Colombia Country Study. Additional technical assistance was provided to INPARES, the Peruvian IPPF affiliate, in the development of an efficient CBD program. In each case the presence of the Council staff in Bogotá significantly improved the quality and timeliness of project activities.

The departure of the Bogota Office representative in December 1983 and the arrival of the new representative in April 1984 resulted in a four month hiatus in the support provided by the office. No consultants were contracted to provide technical assistance during the interim. With the appointment of the new representative, project development continued as planned.

Population Council In-House Project

Project: Pre-Introduction of Advanced Copper-T IUD's

Period: May 17, 1983 to December 31, 1983(a)
Extended to June 30, 1984(b)

Amount: \$75,000

Approved by AID: August 1, 1983(a)
April 10, 1984(b)

Status: Terminated

Purpose: To prepare for international introduction of the advanced
Copper-T intrauterine devices, the TCU 380 and TCU 380Ag.

The specific objectives of this program were to:

- 1) negotiate licensing agreements with international manufacturers developing country government organizations for the manufacture and distribution of the advanced Copper-T IUDs;
- 2) obtain approval of the USFDA;
- 3) inform decision-makers, clinicians, family planning managers, and potential users about these new IUDs.

Licensing agreements had previously been reached with several manufacturers to ensure worldwide availability of both the Copper-T380A and Ag models. USFDA approval of the 380A model was given in 1984. Approval of the 380Ag by the Finnish regulatory authority was given early in 1985. Meetings were held in New York and Washington to brief program and commodities procurement professionals from international population organizations. A package of informational materials for decision-makers, clinicians, field workers and potential acceptors of the Copper-T380 was distributed to family planning leaders in international population organizations and developing countries.

Population Council In-House Project

Project: Design, Implementation and Evaluation of Family Planning
Projects in Sub-Saharan Africa

Period: June 1, 1983 to May 31, 1984(a) Amount: \$134,911(a)
Extended to December 31, 1984(b)
Extended to March 31, 1985(c)
Extended to June 30, 1985(d)

Approved by AID: October 14, 1983(a) Status: Current
March 14, 1984(b)
* (c)
April 15, 1985(d)

*AID approval not required for extension to March 31, 1985 pursuant to terms of Cooperative Agreement No. DPE-3005-A-00-3003-00, Section C, Paragraph 2, Subparagraph f

Purpose: To design, test, and provide technical assistance in monitoring and evaluation of existing family planning programs in Sub-Saharan Africa and to develop and expand family planning programs in Sub-Saharan Africa.

During the period March 1, 1984 to February 28, 1985 the Council carried out the following activities in Zimbabwe, Mali, and Rwanda:

Rwanda: Francine Coeytaux spent two weeks in Rwanda in June to assist the Office National de la Population (ONAPO) in expanding its operations research capabilities. The following technical assistance was provided:

- 1) a four-hour training session on operations research methodology was held, attended by four ONAPO staff members and six people from the Ministry of Health,
- 2) an evaluation questionnaire was designed to assist in evaluating ONAPO's ongoing program activities, and
- 3) three operations research studies were designed in collaboration with the Ministry of Health and ONAPO focusing on the improvement of service delivery. One of the studies, evaluating the impact of pharmaceutical cooperatives on the availability of preventive health services, was designed for submission to PRICORP for funding.

Margaret McEvoy went to Rwanda in April, 1984 to review service statistics system and prepare for 1983 service statistics analysis and to set up collection procedures for 1984.

Zimbabwe: Francine Coeytaux and George Brown both made a trip to Zimbabwe in 1984 to assist the Child Spacing and Family Planning Council of Zimbabwe (CSFPC) in developing operations research studies for the Kubatsirana Pilot Project. The Kubatsirana Project seeks to link family planning to other development activities. The Council assisted in the development of a research study which would explore and test alternative strategies of integrating family planning with other community development activities. The study would also explore the expansion of the existing CBD program and ways in which the family program could benefit from working with women's income generating groups. A research proposal was drawn up and funding for the implementation of the study was requested.

George Brown also explored the possibility of conducting Norplant® introduction studies in Zimbabwe.

Mali: The Council funded two doctors from the Ministry of Health in Mali to attend an eight week workshop in Family Planning Program Management conducted by the International Health Program of the University of California. The workshop was held in Santa Cruz, California beginning March 26, 1984. Both Dr. Bougou Cissoka, Director of Training, Ministry of Health, and Dr. Mamadu Konate, Assistant Medical Officer for Kita, Mali, successfully completed the course.

Population Council In-House Project

Project: Management Consulting for Contraceptive Technologies

Period: July 1, 1983 to June 30, 1984

Amount: \$7,800

Approved by AID: October 24, 1983

Status: Terminated

Purpose: To provide management consulting to AID and AID-supported organizations in the development and regulatory approval of new contraceptive technologies.

The objective of this project was to provide management guidance to AID and AID-supported organizations in the development and regulatory approval of new contraceptive technologies.

During the reporting period, consultation was provided to Family Health International on the development of a long-acting progestin-releasing micro-capsule injectable contraceptive. This project was terminated.

Population Council In-House Project

Project: Pre-Introduction of NORPLANT® Contraceptive Subdermal Implants

Period: January 1, 1984 to February 29, 1984(a) Amount: \$49,100(a)
 Extended to June 30, 1984 (b) \$33,757(b)

Approved by AID: February 16, 1984(a) Status: Terminated
 April 5, 1984(b)

Purpose: To initiate pre-introductory activities designed to make NORPLANT® contraceptive subdermal implants available on a global basis.

The primary goals of the Council's introduction program for NORPLANT® implants are:

- (1) to collaborate with Leiras Pharmaceuticals, the Council's licensee, in securing regulatory approvals, especially in developing countries; and in developing prototype informational and training materials;
- (2) to collaborate with other public sector organizations in establishing training and informational networks in developing countries;
- (3) to provide the opportunity for leading clinicians and family planning leaders to gain first-hand experience with the method;
- (4) to inform decision-makers in the international population community about the NORPLANT® system.

In 1984, Leiras initiated regulatory filings in several countries in Asia, Latin America, Europe and Africa. Approval for distribution was granted in Sweden. NORPLANT® implants had been approved in Finland, the country of manufacture in 1983.

Considerable progress was made in development of training materials. Prototype informational and instruction materials for physicians were produced in Finnish, English, and Spanish. Translations into other languages is in progress. Videotape and slide training aids have also been developed. Materials for counselors are in the concept stage. The Program for Introduction and Adaptation of Contraceptive Technologies (PIACT) has begun development of country specific user informational materials in selected countries.

Utilizing the experience gained in its clinical studies and field trials, the Council initiated the development of training centers in Indonesia, the Dominican Republic, and Chile. These centers extend training for medical personnel within

the country, and provide initial training for clinicians from other countries wishing to gain experience with the method. Discussions have begun with The Johns Hopkins Program for International Education in Gynecology and Obstetrics (JHPIEGO) and the Association for Voluntary Sterilization (AVS) to incorporate the NORPLANT® method into their international training programs.

The Council initiated or developed pre-introduction clinical studies in Brazil, Chile, China, Colombia, the Dominican Republic, and Ecuador. Proposals are in development in Mexico, Kenya, and Zambia. A collaborating organization, Family Health International, started trials in Bangladesh, Nepal, the Philippines, Singapore, and Sri Lanka.

Council staff have been active in informing decision-makers in international population organizations, leading clinicians, family planning managers, and government officials in many countries about the NORPLANT® method. The communication program involved a variety of approaches including scientific literature, presentations at meetings and workshops, newsletters, and individual briefings to specific organizations, including USAID, IPPF, and UNFPA. A major consultation on the NORPLANT® system was convened by WHO to evaluate the pre-clinical and clinical experience with the method and to provide guidance to governments concerning its incorporation into family planning programs.

Population Council In-House Project

Project: Pre-Introduction Evaluation of NORPLANT® Contraceptive
Subdermal Implants

Period: April 1, 1984 to March 31, 1985

Amount: \$108,000(a)
\$191,000(b)
\$ 18,550(c)*

Approved by AID: May 31, 1984(a)
November 8, 1984(b)
June 30, 1985(c)

Status: Current

Purpose: To facilitate the widespread availability and use of NORPLANT^R
Contraceptive Subdermal Implants in family planning programs
throughout the world.

See summary for in-house project of same title for the period January 1, 1984
- February 29, 1984.

Population Council In-House Project

Project: Local Office Expenses,
Bogotá, Colombia

Period: May 1, 1984 to April 30, 1985

Amount: \$30,000 (a)
\$ 6,546 (b)*

Approved by AID: May 2, 1984 (a)
February 12, 1985 (b)

Status: Current

*The additional \$6,546 is from unexpended funds under the in-house project for support of the Bogotá Office for the period May 16, 1983 to April 30, 1984.

Purpose: To monitor and provide technical assistance to AID-funded population activities in the Andean Region.

AID funding for the period May 1, 1984 to April 30, 1985 partially covered PC/Bogotá expenditures incurred in the maintenance of the office such as rent and supplies, local staff support, and computer time. Council staff was funded through specific AID sponsored projects as well as from other sources. The activities of the staff assigned to this office included, a) monitoring of on-going projects; b) assisting in the preparation of work for the implementation of continuing activities; c) provision of technical assistance and, d) preparation of technical and financial reports for supported projects.

Major projects in Colombia during 1984-1985 included the preparation of the final narrative report for the PROFAMILIA rural CBD project, the Fundacion Santa Fe natural family planning project, the CCRP translation and publication program, the final editing and translation of the Colombian Country Study, the development of contraceptive introduction studies (NORPLANT^R), assistance in the organization of a regional seminar on women and health, and finally the renewed effort to produce a videotape describing the role of operations research through the Bogota rural promotor project. In addition, technical assistance was provided to the AID Mission in Peru to prepare an evaluation of the AID health loan to the government of Peru and to assess priority issues in family planning operations research. In each case, the presence of the Council staff in Bogota significantly improved the quality and timeliness of project activities.

The responsibilities of the Bogota office on departure of John Townsend as Bogota office representative in January 1984 were assumed by Dr. Norman Wilde on a consultant basis. Due to the quality of this technical assistance, arrangements are now being made by the Council to extend his consultancy through the next fiscal year. Finally, office funds were utilized to purchase computer equipment for use in the preparation of reports, control of projects, and the analysis of data generated by Council supported and AID supported projects in Colombia and the Andean region.

Population Council In-House Project

Project: Population and Family Planning Programs,
12th edition (FACT BOOK)

Period: January 1, 1985 to December 31, 1985

Amount: \$52,000

Approved by AID: January 15, 1985

Status: Current

Purpose: To produce and distribute the 12th edition of Population and Family Planning Programs.

The twelfth edition of the Fact Book, Population and Family Planning Programs, by Dorothy Nortman, is scheduled for publication in the fall of 1985. This edition of the Fact Book is a compendium of data through 1983. Eighteen tables and the explanatory text compare national and regional demographic, social, and economic characteristics; indicators of family planning input and output; important regulations and costs for contraceptives; government budgets; program expenditures; and time trends in contraceptive practice. A wall chart showing contraceptive use, subdivided by method, among married women of reproductive age in 35 countries and 6 world regions is included.

The compilations have been completed by the author, who was a senior associate in the Council's Center for Policy Studies. She first collected the data by means of a questionnaire to country experts, and then examined, verified, and computerized the data. Nortman has completed the final manuscript and has turned it over to the Office of Communications for editing and publication.

The manuscript is being edited by Office of Communications staff and will go into production this summer. An early fall publication date has been scheduled. Distribution, promotion and review copies, exhibits, and other publishing matters will also be handled by the Office of Communications. Approximately 6500 copies will be published and distributed.

Population program planners, funding agencies, and a wide group of business and research professionals use this compendium, which is widely acknowledged to be the most authoritative and comprehensive collection of reliable statistics on family planning program inputs and outputs worldwide.

III. UPDATED INFORMATION ON EXPIRED AWARDS AND SUBCONTRACTS

AID/DPE-3005-A-00-3003-00

<u>Award/ Subcontract No.</u>	<u>Administering Institution/ Subcontractor</u>	<u>Date of Progress Report Containing Final Substantive Report</u>	<u>Updated Information</u>
B83.37A/ICCR	Salk Institute for Biological Studies	June 1984	Audit by Main Hurdman scheduled to begin by 9/85

IV. LIST OF TERMINATED AWARDS, SUBCONTRACTS AND PROJECTS
(Reporting Completed)

Report Submitted in June 1984
(17 May 1983 - 29 February 1984 Progress Report)

Seminar on NORPLANT® Contraception

V. FINANCIAL INFORMATION ON AWARDS,
SUBCONTRACTS, AND PROJECTS

- January 1, 1984 to March 31, 1984
- April 1, 1984 to June 30, 1984
- July 1, 1984 to September 30, 1984
- October 1, 1984 to December 31, 1984

Not included:

- January 1, 1985 to March 31, 1985
(to be submitted in July 1985)

COOPERATIVE AGREEMENT No. AID/DPE-3005-A-00-3003-00
STATEMENT OF EXPENDITURES

For the Period January 1, 1984 to March 31, 1984

	Budget 5/17/83- 2/28/85(1)	Expended To Date 3/31/84	Expended This Period 1/1/84-3/31/84
<u>In-House Projects</u>			
<u>Center for Biomedical Research</u>			
<u>Contraceptive Ring</u>			
Salaries and Benefits	\$188,795.00	\$ 77,988.00	\$ 18,220.00
Rabbits and Animal Maintenance	2,000.00	2,000.00	2,000.00
Laboratory Supplies	1,000.00	1,000.00	-
Awards and Subcontracts*	144,421.00	19,616.00	-
Technology Transfer	15,896.00	8,896.00	-
<u>Total Direct Costs</u>	<u>352,112.00</u>	<u>109,500.00</u>	<u>20,220.00</u>
<u>Indirect Cost @ 43.84% (\$262,832)</u>	<u>115,225.55</u>	<u>8,864.45</u>	<u>8,864.45</u>
<u>Indirect Cost @ 34.40% (\$89,280)</u>	<u>30,712.32</u>	<u>30,712.32</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>145,937.87</u>	<u>39,576.77</u>	<u>-</u>
<u>Total Direct and Indirect Costs</u>	<u>\$498,049.87</u>	<u>\$149,076.77</u>	<u>\$ 29,084.45</u>
<u>Levonorgestrel IUD</u>			
Salaries and Benefits	\$ 31,280.00	\$ 31,280.00	\$ 238.00
Laboratory Supplies	1,200.00	1,200.00	1,200.00
Awards and Subcontracts*	137,225.00	23,760.00	-
<u>Total Direct Costs</u>	<u>169,705.00</u>	<u>56,240.00</u>	<u>1,438.00</u>
<u>Indirect Cost @ 43.84% (\$114,903)</u>	<u>50,373.48</u>	<u>630.42</u>	<u>630.42</u>
<u>Indirect Cost @ 34.40% (\$54,802)</u>	<u>18,851.89</u>	<u>18,851.89</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>69,225.37</u>	<u>19,482.31</u>	<u>630.42</u>
<u>Total Direct and Indirect Costs</u>	<u>\$238,930.37</u>	<u>\$ 75,722.31</u>	<u>\$ 2,068.42</u>
<u>Subdermal Implants</u>			
Salaries and Benefits	\$259,591.00	\$121,224.00	\$ 4,182.00
Laboratory Supplies	818.00	818.00	-
Awards and Subcontracts*	139,134.00	35,067.00	-
<u>Total Direct Costs</u>	<u>399,543.00</u>	<u>157,109.00</u>	<u>4,182.00</u>
<u>Indirect Cost @ 43.84% (\$246,616)</u>	<u>108,116.45</u>	<u>1,833.39</u>	<u>1,833.39</u>
<u>Indirect Cost @ 34.40% (\$152,927)</u>	<u>52,606.89</u>	<u>52,606.89</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>160,723.34</u>	<u>54,440.28</u>	<u>1,833.39</u>
<u>Total Direct and Indirect Costs</u>	<u>\$560,266.34</u>	<u>\$211,549.28</u>	<u>\$ 6,015.39</u>

* For subcontract details see Appendix A.

	Budget 5/17/83- 2/28/85(1)	Expended To Date 3/31/84	Expended This Period 1/1/84-3/31/84
<u>LHRH Analogs</u>			
Salaries and Benefits	\$ 78,384.00	\$ 43,970.00	\$ 13,970.00
Laboratory Supplies	35,867.00	-	-
Awards and Subcontracts*	21,772.00	13,772.00	13,772.00
<u>Total Direct Costs</u>	<u>136,023.00</u>	<u>57,742.00</u>	<u>27,742.00</u>
<u>Indirect Cost @ 43.84% (\$106,023)</u>	<u>46,480.48</u>	<u>12,162.09</u>	<u>12,162.09</u>
<u>Indirect Cost @ 34.40% (\$30,000)</u>	<u>10,320.00</u>	<u>10,320.00</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>56,800.48</u>	<u>22,482.09</u>	<u>12,162.09</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 192,823.48</u>	<u>\$ 80,224.09</u>	<u>\$ 39,904.09</u>
<u>Food and Drug Administration Filing Assistant</u>			
Consultant Fees	\$ 11,000.00	\$ 11,000.00	\$ -
No Indirect Cost			
<u>Inhibin</u>			
Salaries and Benefits	\$ 7,314.00	\$ 7,314.00	\$ -
Laboratory Supplies	6,000.00	5,000.00	-
Awards and Subcontracts*	477,303.00	109,963.00	26,666.00
<u>Total Direct Costs</u>	<u>490,617.00</u>	<u>122,277.00</u>	<u>26,666.00</u>
<u>Indirect Cost @ 43.84% (\$395,006)</u>	<u>173,170.63</u>	<u>11,690.37</u>	<u>11,690.37</u>
<u>Indirect Cost @ 34.40% (\$95,611)</u>	<u>32,890.17</u>	<u>32,890.19</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>206,060.80</u>	<u>44,580.56</u>	<u>11,690.37</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 696,677.80</u>	<u>\$166,857.56</u>	<u>\$ 38,356.37</u>
<u>Total Obligated Direct Costs-Center for Biomedical Research</u>	<u>\$1,559,000.00</u>	<u>\$513,868.00</u>	<u>\$ 80,248.00</u>
<u>Total Obligated Indirect Costs-Center for Biomedical Research</u>	<u>638,747.86</u>	<u>180,562.01</u>	<u>35,180.72</u>
<u>Total Obligated Direct and Indirect Costs-Center for Biomedical Research</u>	<u>\$2,197,747.86</u>	<u>\$694,430.01</u>	<u>\$115,428.72</u>
<u>International Programs</u>			
<u>Pre-Introduction of Copper-T IUD</u>			
Salaries and Benefits	\$ 35,066.00	\$ 36,950.00	\$ -
Contraceptive Supplies	15,000.00	-	-
Communications and Supplies	1,500.00	1,303.97	-
Travel	5,000.00	2,489.00	-
Meetings	434.00	586.16	-
Legal Fees	18,000.00	24,370.28	-
<u>Total Direct Costs</u>	<u>75,000.00</u>	<u>65,699.41</u>	<u>-</u>

* For subcontract detail see Appendix A.

Cont'd on next page

6/6

	Budget 5/17/83- 6/30/84(1)	Expended To Date 3/31/84	Expended This Period 1/1/84-3/31/84
<u>Indirect Cost @ 38.26% (\$9,300.59)</u>	3,558.41	-	-
<u>Indirect Cost @ 33.28% (\$65,699.41)</u>	21,864.76	21,864.76	-
<u>Total Indirect Costs</u>	25,423.17	21,864.76	-
<u>Total Direct and Indirect Costs</u>	\$ 100,423.17	\$ 87,564.17	\$ -

Norplant Seminar

	Budget 9/15/83- 12/31/83		
Travel and Per Diem	\$ 15,426.00	\$ 12,436.92	\$ 7,026.11
Equipment Rental	1,133.00	1,133.00	1,133.00
Seminar Luncheon	871.00	871.00	(8,729.11)
Translation	570.00	570.00	570.00
Other Direct Costs	2,000.00	3,123.60	(.01)
<u>Total Direct Costs</u>	20,000.00	18,134.52	(.01)
<u>Indirect Cost @ 33.28% (\$20,000.00)</u>	6,656.00	6,035.17	-
<u>Total Direct and Indirect Costs</u>	\$ 26,656.00	\$ 24,169.69	\$ (.01)

Management Consultant

	Budget 7/ 1/83- 6/30/84		
Forrest Greenslade	\$ 7,800.00	\$ 5,558.70	\$ 1,941.36
<u>Indirect Cost @ 38.26% (\$4,182.66)</u>	1,600.29	742.76	742.76
<u>Indirect Cost @ 33.28% (\$3,617.34)</u>	1,203.85	1,203.85	-
<u>Total Indirect Costs</u>	2,804.14	1,946.61	742.76
<u>Total Direct and Indirect Costs</u>	\$ 10,604.14	\$ 7,505.31	\$ 2,684.12

Design, Implementation, Evaluation of
Family Planning Projects in Sub-Saharan
Africa

	Budget 5/17/83- 12/31/84		
Salaries and Benefits	\$ 56,377.00	\$ 24,299.30	\$ 7,763.88
Consultants	11,938.00	2,760.00	-
Travel and Per Diem	38,470.00	13,775.54	4,406.00
Educational Materials	15,267.00	747.10	480.00
Communication	1,259.00	625.36	266.32
Participant Training	11,600.00	-	-
<u>Total Direct Costs</u>	134,911.00	42,207.30	12,916.20
<u>Indirect Cost @ 38.26% (\$105,619.90)</u>	33,508.07	4,941.74	4,941.74
<u>Indirect Cost @ 33.28% (\$26,531.10)</u>	8,829.55	8,829.55	-
<u>Total Indirect Costs</u>	42,337.62	13,771.29	4,941.74
<u>Total Direct and Indirect Costs</u>	\$ 177,248.62	\$ 55,978.59	\$ 17,857.94

	Budget 4/ 1/84- 3/31/85	Expended To Date 3/31/84	Expended This Period 1/1/84-3/31/84
<u>Project on Copper-T IUD Training and Evaluation in Brazil</u>			
Salaries and Benefits	\$ 7,758.00	\$ -	\$ -
Allowances	2,500.00	-	-
Office Expenses	3,000.00	-	-
In-Country Travel	1,500.00	-	-
Sub-Award - CEMICAMP	53,028.00	-	-
<u>Total Direct Costs</u>	67,786.00	-	-
<u>Indirect Cost @ 38.26%</u>	25,934.92	-	-
<u>Total Direct and Indirect Costs</u>	\$ 93,720.92	\$ -	\$ -
	Budget 3/ 1/84- 7/31/85		
<u>Mexican Social Security Institute</u>			
Salaries and Benefits	\$ 9,096.00	\$ -	\$ -
Travel	2,400.00	-	-
Per Diem	1,932.00	-	-
Sub-Award-IMSS	66,136.00	-	-
<u>Total Direct Costs</u>	79,564.00	-	-
<u>Indirect Cost @ 38.26%</u>	30,441.19	-	-
<u>Total Direct and Indirect Costs</u>	\$ 110,005.19	\$ -	\$ -
	Budget 5/16/84- 6/30/85		
<u>International Centre for Diarrhoeal Disease Research, Bangladesh</u>			
Salaries and Benefits	\$ 57,053.76	\$ -	\$ -
Workmen's Compensation Insurance	1,383.24	-	-
Housing	14,520.00	-	-
Education	3,500.00	-	-
Storage	1,350.00	-	-
Night Watchman	450.00	-	-
Travel	6,400.00	-	-
Home Leave	8,800.00	-	-
Automobile	3,938.00	-	-
Relocation Costs	18,062.00	-	-
Communication	945.00	-	-
Miscellaneous Expenses	1,100.00	-	-
Subcontracts to ICDDR	46,392.00	-	-
<u>Total Direct Costs</u>	163,894.00	-	-
<u>Indirect Cost @ 38.26%</u>	62,705.84	-	-
<u>Total Direct and Indirect Costs</u>	\$ 226,599.84	\$ -	\$ -

Cont'd on next page

60

	Budget 4/ 1/84- 3/31/85	Expended To Date 3/31/84	Expended This Period 1/1/84-3/31/84
<u>Pre-Introduction Evaluation of Norplant®</u>			
<u>Contraceptive Subdermal Implants</u>			
Salaries and Benefits	\$ 38,571.00	\$ -	\$ -
Allowances	5,376.00	-	-
Senior Consultants	7,538.00	-	-
Travel and Per Diem	2,265.00	-	-
Subcontract-CONAPOFA	25,000.00	-	-
Subcontract-Mahidol University	9,250.00	-	-
Subcontract-CCRP and PROFAMILIA	20,000.00	-	-
<u>Total Direct Costs</u>	108,000.00	-	-
<u>Indirect Cost @ 38.26%</u>	38,436.76	-	-
<u>Total Direct and Indirect Costs</u>	\$ 146,436.76	\$ -	\$ -

	Budget 1/ 1/84- 6/30/84		
<u>Pre-Introduction of Norplant® Contraceptive</u>			
<u>Subdermal Implants</u>			
Salaries and Benefits	\$ 65,167.00	\$ 70,270.01	\$ 70,270.01
Allowances	8,685.00	4,666.72	4,666.72
Consultants	6,005.00	-	-
Audio Visual Materials	200.00	114.14	114.14
Local Meetings	250.00	273.58	273.58
Communications	2,550.00	1,527.55	1,527.55
<u>Total Direct Costs</u>	82,857.00	76,852.00	76,852.00
<u>Indirect Cost @ 38.26%</u>	29,403.58	29,403.58	29,403.58
<u>Total Direct and Indirect Costs</u>	\$ 112,260.58	\$106,255.58	\$106,255.58

	Budget 1/ 1/84- 12/31/84		
<u>Expanding Health Service Coverage in</u>			
<u>Columbia</u>			
In-House Cost	\$ 14,194.00	\$ -	\$ -
Subcontract	72,995.00	25,000.00	25,000.00
<u>Total Direct Cost</u>	87,189.00	25,000.00	25,000.00
<u>Total Indirect Cost @ 38.26%</u>	33,358.51	9,565.00	9,565.00
<u>Total Direct and Indirect Costs</u>	\$ 120,547.51	\$ 34,565.00	\$ 34,565.00

Cont'd on next page

69

	<u>Budget</u> 1/ 1/84- 12/31/84	<u>Expended</u> <u>To Date</u> 3/31/84	<u>Expended</u> <u>This Period</u> 1/1/84-3/31/84
<u>Total Obligated Direct Cost</u> <u>International Programs</u>	\$ 827,001.00	\$ 233,451.93	\$116,709.55
<u>Total Obligated Indirect Costs</u> <u>International Programs</u>	297,501.73	82,586.41	44,653.08
<u>Total Obligated Direct and Indirect</u> <u>Costs - International Programs</u>	<u>\$1,124,502.73</u>	<u>\$ 316,038.34</u>	<u>\$161,362.63</u>
<u>Management Support Services-Bogota Office</u>			
Salaries and Benefits	\$ 22,000.00	\$ 11,741.87	\$ 3,335.27
Travel	11,000.00	465.05	-
Expendable Supplies	4,000.00	228.54	1.74
Rent	12,000.00	3,825.00	-
Communication	5,000.00	1,609.90	82.18
Other Direct Costs	6,000.00	2,004.26	181.48
<u>Total Direct Costs</u>	<u>60,000.00</u>	<u>19,874.62</u>	<u>3,600.67</u>
<u>Indirect Cost @ 12% (\$16,273.94)</u>	1,952.87	1,952.87	-
<u>Indirect Cost @ 11.5% (\$43,726.05)</u>	5,028.50	414.08	414.08
<u>Total Indirect Costs</u>	<u>6,981.37</u>	<u>2,366.95</u>	<u>414.08</u>
<u>Total Direct and Indirect Costs</u> <u>Management Support Services</u>	<u>\$ 66,981.37</u>	<u>\$ 22,241.57</u>	<u>\$ 4,014.75</u>
<u>TOTAL DIRECT COSTS ALL DIVISIONS</u>	<u>\$2,446,001.00</u>	<u>\$ 767,194.55</u>	<u>\$200,558.22</u>
<u>TOTAL INDIRECT COSTS ALL DIVISIONS</u>	<u>943,230.96</u>	<u>265,515.37</u>	<u>80,247.88</u>
<u>TOTAL DIRECT AND INDIRECT COSTS</u> <u>ALL DIVISIONS</u>	<u>\$3,389,231.96</u>	<u>\$1,032,709.92</u>	<u>\$280,806.10</u>

The undersigned hereby certifies: (A) That payment of the sum claimed under the cited agreement is proper and due and that appropriate refund to AID will be made promptly upon request in the event of disallowance of costs not reimbursable under the terms of the agreement, (B) That information on the fiscal report is correct and such detailed supporting information as AID may reasonably require will be furnished promptly to AID on request at the Contractor's home office or base office as appropriate and (C) That all requirements called for by the agreement to the date of this certification have been met.

By: 
George A. Babb

Title: Assistant Treasurer
and Comptroller

Date: October 17, 1984

Contraceptive Development Program increased by \$788,000.00 Direct Cost
er Amendment No. 3, dated 3/1/84.

New Provisional Indirect Cost Rates per Agreement dated 9/10/84, signed
by J. Derry effective 1/1/84 (see attachment B).

The Population CouncilCOOPERATIVE AGREEMENT No. AID/DPE-3005-A-00-3003-00
STATEMENT OF EXPENDITURESFor the Period January 1, 1984 to March 31, 1984Center for Biomedical Research
Contraceptive Development Program Subcontracts

	<u>Budget</u> 5/17/83- 2/28/85	<u>Expended</u> To Date 3/31/84	<u>Expended</u> This Period 1/1/84-3/31/84
<u>Subdermal Implants - Subcontracts</u>			
CB83.53A/ICCR-Professional Staff Association of the LAC/USC Medical Center	\$ 42,134.00	\$ 21,067.00	\$ -
CB83.61A/ICCR-Professional Staff Association of the LAC/USC Medical Center	14,000.00	14,000.00	-
CB84..01A/ICCR-Centro Nacional de la Familia	<u>31,000.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>87,134.00</u>	<u>35,067.00</u>	<u>-</u>
<u>Contraceptive Rings - Subcontracts</u>			
CB83.54A/ICCR-The George Washington University	39,232.00	19,616.00	-
CB84.02A/ICCR-Emory University School of Medicine	<u>72,689.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>111,921.00</u>	<u>19,616.00</u>	<u>-</u>
<u>Levonorgestrel IUD-Subcontracts</u>			
CB83.66A/ICCR-Professional Staff Association of the LAC/USC Medical Center	47,520.00	23,760.00	-
CB84.09A/ICCR-PROFAMILIA, Dominican Republic	23,616.00	-	-
CB84.14A/ICCR-Technologia Institute, Brazil	<u>18,000.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>89,136.00</u>	<u>23,760.00</u>	<u>-</u>
<u>LHRH Analogs- Subcontracts</u>			
CB83.72A/ICCR-Professional Staff Association of the LAC/USC Medical Center	13,772.00	13,772.00	13,772.00
CB84.07A/ICCR-Urologische Abteilung, Austria	<u>8,000.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>21,772.00</u>	<u>13,772.00</u>	<u>13,772.00</u>
<u>Inhibin - Subcontracts</u>			
CB83.37A/ICCR-Salk Institute, California	83,297.00	83,297.00	-
CB83.79A/ICCR-Salk Institute, California	106,666.00	26,666.00	26,666.00
CB84.10A/ICCR-Florida Institute of Technology	<u>30,340.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>220,303.00</u>	<u>109,963.00</u>	<u>26,666.00</u>
<u>Total Subcontracts-Contraceptive</u> <u>Development Program</u>	<u>\$530,266.00</u>	<u>\$202,178.00</u>	<u>\$ 40,438.00</u>

COOPERATIVE AGREEMENT No. AID/DPE-3005-A-00-3003-00
STATEMENT OF EXPENDITURESFor the Period April 1, 1984 to June 30, 1984

	Budget 5/17/83- 2/28/85(1)	Expended To Date 6/30/84	Expended This Period 4/1/84-6/30/84
<u>In-House Projects</u>			
<u>Center for Biomedical Research</u>			
<u>Contraceptive Ring</u>			
Salaries and Benefits	\$188,795.00	\$108,208.09	\$ 30,220.09
Rabbits and Animal Maintenance	2,000.00	10,718.98	8,718.98
Laboratory Supplies	1,000.00	2,696.02	1,696.02
Awards and Subcontracts*	144,421.00	43,847.00	24,231.00
Technology Transfer	15,896.00	8,896.00	-
<u>Total Direct Costs</u>	<u>352,112.00</u>	<u>174,366.09</u>	<u>64,866.09</u>
<u>Indirect Cost @ 43.84% (\$262,832)</u>	<u>115,225.55</u>	<u>37,301.74</u>	<u>28,437.29</u>
<u>Indirect Cost @ 34.40% (\$89,280)</u>	<u>30,712.32</u>	<u>30,712.32</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>145,937.87</u>	<u>68,014.06</u>	<u>28,437.29</u>
<u>Total Direct and Indirect Costs</u>	<u>\$498,049.87</u>	<u>\$242,380.15</u>	<u>\$ 93,303.38</u>
<u>Levonorgestrel IUD</u>			
Salaries and Benefits	\$ 31,280.00	\$ 31,280.00	\$ -
Laboratory Supplies	1,200.00	1,200.00	-
Awards and Subcontracts*	137,225.00	58,551.00	34,791.00
<u>Total Direct Costs</u>	<u>169,705.00</u>	<u>91,031.00</u>	<u>34,791.00</u>
<u>Indirect Cost @ 43.84% (\$114,903)</u>	<u>50,373.48</u>	<u>15,882.79</u>	<u>15,252.37</u>
<u>Indirect Cost @ 34.40% (\$54,802)</u>	<u>18,851.89</u>	<u>18,851.89</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>69,225.37</u>	<u>34,734.68</u>	<u>15,252.37</u>
<u>Total Direct and Indirect Costs</u>	<u>\$238,927.37</u>	<u>\$125,765.68</u>	<u>\$ 50,043.37</u>
<u>Subdermal Implants</u>			
Salaries and Benefits	\$259,591.00	\$158,960.45	\$ 37,736.45
Laboratory Supplies	818.00	818.00	-
Awards and Subcontracts*	139,134.00	71,634.00	36,567.00
<u>Total Direct Costs</u>	<u>399,543.00</u>	<u>231,412.45</u>	<u>74,303.45</u>
<u>Indirect Cost @ 43.84% (\$246,616)</u>	<u>108,116.45</u>	<u>34,408.02</u>	<u>32,574.63</u>
<u>Indirect Cost @ 34.40% (\$152,927)</u>	<u>52,606.89</u>	<u>52,606.89</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>160,723.34</u>	<u>87,014.91</u>	<u>32,574.63</u>
<u>Total Direct and Indirect Costs</u>	<u>\$560,266.34</u>	<u>\$318,427.36</u>	<u>\$106,878.08</u>

* For subcontract details see Appendix A.

	Budget 5/17/83- 2/28/85(1)	Expended To Date 6/30/84	Expended This Period 4/1/84-6/30/84
<u>LHRH Analogs</u>			
Salaries and Benefits	\$ 78,384.00	\$ 53,355.64	\$ 9,385.64
Laboratory Supplies	35,867.00	49.20	49.20
Awards and Subcontracts*	21,772.00	21,772.00	8,000.00
<u>Total Direct Costs</u>	<u>136,023.00</u>	<u>75,176.84</u>	<u>17,434.84</u>
<u>Indirect Cost @ 43.84% (\$106,023)</u>	46,480.48	19,805.52	7,643.43
<u>Indirect Cost @ 34.40% (\$30,000)</u>	10,320.00	10,320.00	-
<u>Total Indirect Costs</u>	<u>56,800.48</u>	<u>30,125.52</u>	<u>7,643.43</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 192,823.48</u>	<u>\$ 105,302.36</u>	<u>\$ 25,078.27</u>
<u>Food and Drug Administration Filing Assistant</u>			
Consultant Fees	\$ 11,000.00	\$ 11,000.00	\$ -
<u>No Indirect Cost</u>			
<u>Inhibin</u>			
Salaries and Benefits	\$ 7,314.00	\$ 7,314.00	\$ -
Laboratory Supplies	6,000.00	6,000.00	1,000.00
Awards and Subcontracts*	477,303.00	205,133.00	95,170.00
<u>Total Direct Costs</u>	<u>490,617.00</u>	<u>218,447.00</u>	<u>96,170.00</u>
<u>Indirect Cost @ 43.84% (\$395,006)</u>	173,170.63	53,851.30	42,160.93
<u>Indirect Cost @ 34.40% (\$95,611)</u>	32,890.17	32,890.19	-
<u>Total Indirect Costs</u>	<u>206,060.80</u>	<u>86,741.49</u>	<u>42,160.93</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 696,677.80</u>	<u>\$ 305,188.49</u>	<u>\$138,330.93</u>
<u>Total Obligated Direct Costs-Center for Biomedical Research</u>	<u>\$1,559,000.00</u>	<u>\$ 801,433.38</u>	<u>\$287,565.38</u>
<u>Total Obligated Indirect Costs-Center for Biomedical Research</u>	<u>638,747.86</u>	<u>306,630.66</u>	<u>126,068.65</u>
<u>Total Obligated Direct and Indirect Costs-Center for Biomedical Research</u>	<u>\$2,197,747.86</u>	<u>\$1,108,064.04</u>	<u>\$413,634.03</u>
<u>International Programs</u>			
<u>Pre-Introduction of Copper-T IUD</u>			
Salaries and Benefits	\$ 35,066.00	\$ 36,950.00	\$ -
Contraceptive Supplies	15,000.00	-	-
Communications and Supplies	1,500.00	1,303.97	-
Travel	5,000.00	2,489.00	-
Meetings	434.00	647.38	61.22
Legal Fees	18,000.00	29,255.16	4,884.88
<u>Total Direct Costs</u>	<u>75,000.00</u>	<u>70,645.51</u>	<u>4,946.10</u>

* For subcontract detail see Appendix A.

	Budget 5/17/83- 6/30/84(1)	Expended To Date 6/30/84	Expended This Period 4/1/84-6/30/84
<u>Indirect Cost @ 38.26% (\$9,300.59)</u>	\$ 3,558.41	\$ 1,892.38	\$ 1,892.38
<u>Indirect Cost @ 33.28% (\$65,699.41)</u>	21,864.76	21,864.76	-
<u>Total Indirect Costs</u>	25,423.17	23,757.14	1,892.38
<u>Total Direct and Indirect Costs</u>	\$ 100,423.17	\$ 94,402.65	\$ 6,838.48
	Budget 9/15/83- 12/31/83		
<u>Norplant Seminar</u>	\$ 15,426.00	\$ 12,436.92	\$ -
Travel and Per Diem	1,133.00	1,133.00	-
Equipment Rental	871.00	871.00	-
Seminar Luncheon	570.00	570.00	-
Translation	2,000.00	3,123.60	-
Other Direct Costs			
<u>Total Direct Costs</u>	20,000.00	18,134.52	-
<u>Indirect Cost @ 33.28% (\$20,000.00)</u>	6,656.00	6,035.17	-
<u>Total Direct and Indirect Costs</u>	\$ 26,656.00	\$ 24,169.69	\$ -
	Budget 7/ 1/83- 6/30/84		
<u>Management Consultant</u>	\$ 7,800.00	\$ 6,241.70	\$ 683.00
Forrest Greenslade			
<u>Indirect Cost @ 38.26% (\$4,182.66)</u>	1,600.29	1,004.08	261.32
<u>Indirect Cost @ 33.28% (\$3,617.34)</u>	1,203.85	1,203.85	-
<u>Total Indirect Costs</u>	2,804.14	2,207.93	261.32
<u>Total Direct and Indirect Costs</u>	\$ 10,604.14	\$ 8,449.63	\$ 944.32
	Budget 5/17/83- 12/31/84		
<u>Design, Implementation, Evaluation of Family Planning Projects in Sub-Saharan Africa</u>	\$ 51,377.00	\$ 34,065.62	\$ 9,766.32
Salaries and Benefits	11,938.00	2,760.00	-
Consultants	38,470.00	17,561.61	3,786.07
Travel and Per Diem	15,267.00	747.10	-
Educational Materials	1,259.00	727.61	102.25
Communication	16,600.00	-	-
Participant Training			
<u>Total Direct Costs</u>	134,911.00	55,861.94	13,654.64
<u>Indirect Cost @ 38.26% (\$105,619.90)</u>	33,508.07	10,166.01	5,224.27
<u>Indirect Cost @ 33.28% (\$26,531.10)</u>	8,829.55	8,829.55	-
<u>Total Indirect Costs</u>	42,337.62	18,995.56	5,224.27
<u>Total Direct and Indirect Costs</u>	\$ 177,248.62	\$ 74,857.50	\$ 18,878.91

	Budget 4/ 1/84- 3/31/85	Expended To Date 6/30/84	Expended This Period 4/1/84-6/30/84
<u>Project on Copper-T IUD Training and Evaluation in Brazil</u>			
Salaries and Benefits	\$ 7,758.00	\$ 2,131.65	\$ 2,131.65
Allowances	2,500.00	160.19	160.19
Office Expenses	3,000.00	434.96	434.96
In-Country Travel	1,500.00	26.29	26.29
Sub-Award - CEMICAMP	<u>53,028.00</u>	<u>10,000.00</u>	<u>10,000.00</u>
<u>Total Direct Costs</u>	67,786.00	12,753.09	12,753.09
<u>Indirect Cost @ 38.26%</u>	<u>25,934.92</u>	<u>4,879.33</u>	<u>4,879.33</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 93,720.92</u>	<u>\$ 17,632.42</u>	<u>\$ 17,632.42</u>
	Budget 3/ 1/84- 7/31/85		
<u>Mexican Social Security Institute</u>			
Salaries and Benefits	\$ 9,096.00	\$ -	\$ -
Travel	2,400.00	367.33	367.33
Per Diem	1,932.00	-	-
Sub-Award-IMSS	<u>66,136.00</u>	<u>20,000.00</u>	<u>20,000.00</u>
<u>Total Direct Costs</u>	79,564.00	20,367.33	20,367.33
<u>Indirect Cost @ 38.26%</u>	<u>30,441.19</u>	<u>7,792.54</u>	<u>7,792.54</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 110,005.19</u>	<u>\$ 28,159.87</u>	<u>\$ 28,159.87</u>
	Budget 5/16/84- 6/30/85		
<u>International Centre for Diarrhoeal Disease Research, Bangladesh</u>			
Salaries and Benefits	\$ 57,053.76	\$ 6,239.87	\$ 6,239.87
Workmen's Compensation Insurance	1,383.24	-	-
Housing	14,520.00	-	-
Education	3,500.00	-	-
Storage	1,350.00	-	-
Night Watchman	450.00	-	-
Travel	6,400.00	-	-
Home Leave	8,800.00	-	-
Automobile	3,938.00	-	-
Relocation Costs	18,062.00	-	-
Communication	945.00	-	-
Miscellaneous Expenses	1,100.00	-	-
Subcontracts to ICDDR	<u>46,392.00</u>	<u>-</u>	<u>-</u>
<u>Total Direct Costs</u>	163,894.00	6,239.87	6,239.87
<u>Indirect Cost @ 38.26%</u>	<u>62,705.84</u>	<u>2,387.37</u>	<u>2,387.37</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 226,599.84</u>	<u>\$ 8,627.24</u>	<u>\$ 8,627.24</u>

Cont'd on next page

15

	Budget 4/ 1/84- 3/31/85	Expended To Date 6/30/84	Expended This Period 4/1/84-6/30/84
<u>Pre-Introduction Evaluation of Norplant®</u>			
<u>Contraceptive Subdermal Implants</u>			
Salaries and Benefits	\$ 38,571.00	\$ 8,877.63	\$ 8,877.63
Allowances	5,376.00	1,993.25	1,993.25
Senior Consultants	7,538.00	-	-
Travel and Per Diem	2,265.00	225.00	225.00
Subcontract-CONAPOFA	25,000.00	-	-
Subcontract-Mahidol University	9,250.00	3,500.00	3,500.00
Subcontract-CCRP and PROFAMILIA	20,000.00	-	-
<u>Total Direct Costs</u>	108,000.00	14,595.88	14,595.88
<u>Indirect Cost @ 38.26%</u>	38,436.76	5,584.38	5,584.38
<u>Total Direct and Indirect Costs</u>	\$ 146,436.76	\$ 20,180.26	\$20,180.26

	Budget 1/ 1/84- 6/30/84		
<u>Pre-Introduction of Norplant® Contraceptive</u>			
<u>Subdermal Implants</u>			
Salaries and Benefits	\$ 65,167.00	\$ 70,270.01	\$ -
Allowances	8,685.00	5,541.13	874.41
Consultants	6,005.00	1,955.00	1,955.00
Audio Visual Materials	200.00	114.14	-
Local Meetings	250.00	273.58	-
Communications	2,550.00	2,903.14	1,375.59
<u>Total Direct Costs</u>	82,857.00	81,057.00	4,205.00
<u>Indirect Cost @ 38.26%</u>	29,403.58	30,264.43	860.85
<u>Total Direct and Indirect Costs</u>	\$ 112,260.58	\$111,321.43	\$ 5,065.85

	Budget 1/ 1/84- 12/31/84		
<u>Expanding Health Service Coverage in</u>			
<u>Columbia</u>			
Salaries and Benefits	\$ 10,064.00	\$ 5,829.07	\$ 5,829.07
Allowances	4,130.00	337.09	337.09
Subcontract	72,995.00	25,000.00	-
<u>Total Direct Cost</u>	87,189.00	31,166.16	6,166.16
<u>Total Indirect Cost @ 38.26%</u>	33,358.51	11,924.17	2,359.17
<u>Total Direct and Indirect Costs</u>	\$ 120,547.51	\$ 43,090.33	\$ 8,525.33

Cont'd on next page

76

	<u>Budget</u> 1/ 1/84- 12/31/84	<u>Expended</u> To Date 6/30/84	<u>Expended</u> This Period 4/1/84-6/30/84
<u>Total Obligated Direct Cost</u> <u>International Programs</u>	\$ 827,001.00	\$ 317,063.00	\$ 83,611.07
<u>Total Obligated Indirect Costs</u> <u>International Programs</u>	297,501.73	113,828.02	31,241.61
<u>Total Obligated Direct and Indirect</u> <u>Costs - International Programs</u>	<u>\$1,124,502.73</u>	<u>\$ 430,891.02</u>	<u>\$114,852.68</u>
<u>Management Support Services-Bogota Office</u>			
Salaries and Benefits	\$ 22,000.00	\$ 13,965.22	\$ 2,223.35
Travel	11,000.00	1,053.04	587.99
Expendable Supplies	4,000.00	348.68	120.14
Rent	12,000.00	5,175.00	1,350.00
Communication	5,000.00	1,994.34	384.44
Other Direct Costs	6,000.00	2,155.06	150.80
<u>Total Direct Costs</u>	<u>60,000.00</u>	<u>24,691.34</u>	<u>4,816.72</u>
<u>Indirect Cost @ 12% (\$16,273.94)</u>	1,952.87	1,952.87	-
<u>Indirect Cost @ 11.5% (\$43,726.06)</u>	5,028.50	968.00	553.92
<u>Total Indirect Costs</u>	<u>6,981.37</u>	<u>2,920.87</u>	<u>553.92</u>
<u>Total Direct and Indirect Costs</u> <u>Management Support Services</u>	<u>\$ 66,981.37</u>	<u>\$ 27,612.21</u>	<u>\$ 5,370.64</u>
<u>TOTAL DIRECT COSTS ALL DIVISIONS</u>	<u>\$2,446,001.00</u>	<u>\$1,143,187.72</u>	<u>\$375,993.17</u>
<u>TOTAL INDIRECT COSTS ALL DIVISIONS</u>	<u>943,230.96</u>	<u>423,379.55</u>	<u>157,864.18</u>
<u>TOTAL DIRECT AND INDIRECT COSTS</u> <u>ALL DIVISIONS</u>	<u>\$3,389,231.96</u>	<u>\$1,566,567.27</u>	<u>\$533,857.35</u>

The undersigned hereby certifies: (A) That payment of the sum claimed under the cited agreement is proper and due and that appropriate refund to AID will be made promptly upon request in the event of disallowance of costs not reimbursable under the terms of the agreement, (B) That information on the fiscal report is correct and such detailed supporting information as AID may reasonably require will be furnished promptly to AID on request at the Contractor's home office or base office as appropriate and (C) That all requirements called for by the agreement to the date of this certification have been met.

By: 
George A. Babb

Title: Assistant Treasurer
and Comptroller

Date: October 31, 1984

Contraceptive Development Program increased by \$788,000.00 Direct Cost per Amendment No. 3, dated 3/1/84.

New Provisional Indirect Cost Rates per Agreement dated 9/10/84, signed by J. Derry effective 1/1/84 (see attachment B).

111

COOPERATIVE AGREEMENT No. AID/DPE-3005-A-J-3003-00

STATEMENT OF EXPENDITURES

For the Period April 1, 1984 to June 30, 1984

Center for Biomedical Research
Contraceptive Development Program Subcontracts

	<u>Budget</u> <u>5/17/83-</u> <u>2/28/85</u>	<u>Expended</u> <u>To Date</u> <u>6/30/84</u>	<u>Expended</u> <u>This Period</u> <u>4/1/84-6/30/84</u>
<u>Subdermal Implants - Subcontracts</u>			
CB83.53A/ICCR-Professional Staff Association of the LAC/USC Medical Center	\$ 42,134.00	\$ 42,134.00	\$ 21,067.00
CB83.61A/ICCR-Professional Staff Association of the LAC/USC Medical Center	14,000.00	14,000.00	-
CB84.01A/ICCR-Centro Nacional de la Familia	31,000.00	15,500.00	15,500.00
CB84.30A/ICCR-University of Helsinki, Finland	<u>15,000.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>102,134.00</u>	<u>71,634.00</u>	<u>36,567.00</u>
<u>Contraceptive Rings - Subcontracts</u>			
CB83.54A/ICCR-The George Washington University	39,232.00	19,616.00	-
CB84.02A/ICCR-Emory University School of Medicine	72,689.00	24,231.00	24,231.00
CB84.20A/ICCR-The George Washington University	29,625.00	-	-
CB84.25A/ICCR-The George Washington University	<u>48,044.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>188,590.00</u>	<u>43,847.00</u>	<u>24,231.00</u>
<u>Levonorgestrel IUD-Subcontracts</u>			
CB83.66A/ICCR-Professional Staff Association of the LAC/USC Medical Center	47,520.00	23,760.00	-
CB84.09A/ICCR-PROFAMILIA, Dominican Republic	23,616.00	12,638.00	12,638.00
CB84.14A/ICCR-Technologia Institute, Brazil	18,000.00	9,000.00	9,000.00
CB84.18A/ICCR-Argus Research Labs., Inc.	<u>26,306.00</u>	<u>13,153.00</u>	<u>13,153.00</u>
<u>Total</u>	<u>115,442.00</u>	<u>58,551.00</u>	<u>34,791.00</u>
<u>LHRH Analogs- Subcontracts</u>			
CB83.72A/ICCR-Professional Staff Association of the LAC/USC Medical Center	13,772.00	13,772.00	-
CB84.07A/ICCR-Urologische Abteilung, Austria	<u>8,000.00</u>	<u>8,000.00</u>	<u>8,000.00</u>
<u>Total</u>	<u>21,772.00</u>	<u>21,772.00</u>	<u>8,000.00</u>
<u>Inhibin - Subcontracts</u>			
CB83.37A/ICCR-Salk Institute, California	83,297.00	83,297.00	-
CB83.79A/ICCR-Salk Institute, California	106,666.00	106,666.00	80,000.00
CB84.10A/ICCR-Florida Institute of Technology	30,340.00	15,170.00	15,170.00
CB84.27A/ICCR-Salk Institute, California	<u>257,000.00</u>	<u>-</u>	<u>-</u>
<u>Total</u>	<u>477,303.00</u>	<u>205,133.00</u>	<u>95,170.00</u>
<u>Total Subcontracts-Contraceptive</u> <u>Development Program</u>	<u>\$905,241.00</u>	<u>\$400,937.00</u>	<u>\$198,759.00</u>

The Population Council

COOPERATIVE AGREEMENT No. AID/DPE-3005-A-00-3003-00
STATEMENT OF EXPENDITURES

For the Period July 1, 1984 to September 30, 1984

	<u>Budget</u> <u>5/17/83-</u> <u>5/16/84</u>	<u>Expended</u> <u>To Date</u> <u>5/16/84</u>	<u>Expended</u> <u>This Period</u> <u>7/1/84-9/30/84</u>
<u>In-House Projects</u>			
<u>Center for Biomedical Research</u>			
<u>Contraceptive Ring (1)</u>			
Salaries and Benefits	\$ 77,988.00	\$ 77,988.00	\$ -
Rabbits and Animal Maintenance	2,000.00	2,000.00	(8,718.98)
Laboratory Supplies	1,000.00	1,000.00	(1,696.02)
Awards and Subcontracts*	111,921.00	63,463.00	19,616.00
Technology Transfer	8,896.00	8,896.00	-
<u>Total Direct Costs</u>	<u>201,805.00</u>	<u>153,347.00</u>	<u>9,201.00</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Contraceptive Ring (2)</u>			
Salaries and Benefits	95,193.00	57,329.30	27,109.21
Awards and Subcontracts*	92,669.00	14,812.50	14,812.50
<u>Total Direct Costs</u>	<u>187,862.00</u>	<u>72,141.80</u>	<u>41,921.71</u>
<u>Total Direct Cost Contraceptive Rings</u>	<u>389,667.00</u>	<u>225,488.80</u>	<u>51,122.71</u>
<u>Indirect Cost @ 43.84%</u>	<u>162,401.98</u>	<u>90,426.26</u>	<u>22,412.20</u>
<u>Total Direct and Indirect Costs</u>	<u>\$552,068.98</u>	<u>\$315,915.06</u>	<u>\$ 73,534.91</u>
	<u>5/17/83-</u> <u>5/16/84</u>	<u>5/16/84</u>	<u>7/1/84-9/30/84</u>
<u>Levonorgestrel IUD (1)</u>			
Salaries and Benefits	\$ 31,280.00	\$ 31,280.00	\$ -
Laboratory Supplies	1,200.00	1,200.00	-
Awards and Subcontracts*	47,520.00	23,760.00	-
<u>Total Direct Costs</u>	<u>80,000.00</u>	<u>56,240.00</u>	<u>-</u>
	<u>3/ 1/84-</u> <u>3/28/87</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Levonorgestrel IUD (2)</u>			
Awards and Subcontracts*	\$ 88,922.00	\$ 47,944.00	\$ 13,153.00
<u>Total Direct Costs</u>	<u>88,922.00</u>	<u>47,944.00</u>	<u>13,153.00</u>
<u>Total Direct Cost Levonorgestrel</u>	<u>168,922.00</u>	<u>104,184.00</u>	<u>13,153.00</u>
<u>Indirect Cost @ 43.84%</u>	<u>68,882.10</u>	<u>40,500.96</u>	<u>5,766.28</u>
<u>Total Direct and Indirect Costs</u>	<u>\$237,804.10</u>	<u>\$144,684.96</u>	<u>\$ 18,919.28</u>

*For subcontract detail see Appendix A

	<u>Budget</u> 5/16/83- 5/15/84(1)	<u>Expended</u> To Date 5/15/84	<u>Expended</u> This Period 7/1/84-9/30/84
Subdermal Implants (1)			
Salaries and Benefits	\$121,224.00	\$121,224.00	\$ -
Laboratory Supplies	818.00	818.00	-
Awards and Subcontracts*	87,134.00	71,634.00	-
<u>Total Direct Costs</u>	<u>209,176.00</u>	<u>193,676.00</u>	<u>-</u>
	<u>3/ 1/84- 2/28/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
Subdermal Implants (2)			
Salaries and Benefits	138,367.00	81,223.10	43,486.65
Awards and Contracts*	347,147.00	7,500.00	7,500.00
<u>Total Direct Costs</u>	<u>485,514.00</u>	<u>88,723.10</u>	<u>50,986.65</u>
<u>Total Direct Cost Subdermal Implants</u>	<u>694,690.00</u>	<u>282,399.10</u>	<u>50,986.65</u>
<u>Indirect Cost @ 43.84%</u>	<u>290,115.79</u>	<u>109,367.46</u>	<u>22,352.55</u>
<u>Total Direct and Indirect Costs</u>	<u>\$984,805.79</u>	<u>\$391,766.56</u>	<u>\$ 73,339.20</u>
	<u>5/16/83- 5/15/84</u>	<u>5/15/84</u>	<u>7/1/84-9/30/84</u>
LHRH Analogs (1)			
Salaries and Benefits	\$ 43,970.00	\$ 43,970.00	\$ 13,970.00
Awards and Subcontracts*	21,772.00	21,772.00	-
<u>Total Direct Costs</u>	<u>65,742.00</u>	<u>65,742.00</u>	<u>13,970.00</u>
	<u>3/ 1/84- 2/28/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
LHRH Analogs (2)			
Salaries and Benefits	34,414.00	21,714.70	(1,640.94)
Laboratory Supplies	35,867.00	15,158.30	15,109.10
Awards and Subcontracts*	16,230.00	-	-
<u>Total Direct Costs</u>	<u>86,511.00</u>	<u>36,873.00</u>	<u>13,468.16</u>
<u>Total Direct Cost LHRH Analogs</u>	<u>152,253.00</u>	<u>102,615.00</u>	<u>27,438.16</u>
<u>Indirect Cost @ 43.84%</u>	<u>63,915.72</u>	<u>42,154.41</u>	<u>12,028.89</u>
<u>Total Direct and Indirect Costs</u>	<u>\$216,168.72</u>	<u>\$144,769.41</u>	<u>\$ 39,467.05</u>
	<u>5/16/83- 5/15/84</u>	<u>5/15/84</u>	<u>7/1/84-9/30/84</u>
Food and Drug Administration Filing Assistant			
Consultant Fees	\$ 11,000.00	\$ 11,000.00	\$ -
<u>No Indirect Cost</u>	<u></u>	<u></u>	<u></u>

* For subcontract details see Appendix A.

	<u>Budget</u> <u>5/16/83-</u> <u>5/15/84</u>	<u>Expended</u> <u>To Date</u> <u>5/15/84</u>	<u>Expended</u> <u>This Period</u> <u>7/1/84-9/30/84</u>
<u>Inhibin (1)</u>			
Salaries and Benefits	\$ 7,314.00	\$ 7,314.00	\$ -
Laboratory Supplies	6,000.00	6,000.00	-
Awards and Subcontracts*	189,963.00	189,953.00	-
<u>Total Direct Costs</u>	<u>203,277.00</u>	<u>203,277.00</u>	<u>-</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Inhibin (2)</u>			
Awards and Subcontracts*	287,400.00	143,709.00	128,539.00
<u>Total Direct Costs</u>	<u>287,400.00</u>	<u>143,709.00</u>	<u>128,539.00</u>
<u>Total Direct Cost Inhibin</u>	<u>490,677.00</u>	<u>346,986.00</u>	<u>128,539.00</u>
<u>Indirect Cost @ 43.84%</u>	<u>206,087.12</u>	<u>143,092.99</u>	<u>56,351.50</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 696,764.12</u>	<u>\$ 490,078.99</u>	<u>\$184,890.50</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Gonadotropin-Surge-Inhibiting Factor</u>			
Salaries and Benefits	\$ 5,865.00	\$ 2,226.00	\$ 2,226.00
HPLC Columns	5,000.00	-	-
Laboratory Supplies	7,500.00	4,224.50	4,224.50
Awards and Subcontracts*	233,635.00	-	-
<u>Total Direct Costs</u>	<u>252,000.00</u>	<u>6,450.50</u>	<u>6,450.50</u>
<u>Indirect Cost @ 43.84%</u>	<u>110,476.80</u>	<u>2,827.90</u>	<u>2,827.90</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 362,476.80</u>	<u>\$ 9,278.40</u>	<u>\$ 9,278.40</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Tolnidamine</u>			
Salaries and Benefits	\$ 54,270.00	\$ 15,006.60	\$ 15,006.60
Animal Maintenance	79,210.00	8,926.26	8,926.26
<u>Total Direct Costs</u>	<u>133,480.00</u>	<u>23,932.86</u>	<u>23,932.86</u>
<u>Indirect Cost @ 43.84%</u>	<u>58,517.63</u>	<u>10,492.17</u>	<u>10,492.17</u>
<u>Total Direct and Indirect Costs</u>	<u>191,997.63</u>	<u>34,425.03</u>	<u>34,425.03</u>
<u>Total Direct Costs Costs-Center</u> <u>for Biomedical Research</u>	<u>2,292,689.00</u>	<u>1,103,056.26</u>	<u>301,622.88</u>
<u>Total Indirect Costs-Center</u> <u>for Biomedical Research</u>	<u>960,397.14</u>	<u>438,862.15</u>	<u>132,231.49</u>
<u>Total Direct and Indirect Costs-</u> <u>Center for Biomedical Research</u>	<u>\$3,253,086.14</u>	<u>\$1,541,918.41</u>	<u>\$433,854.37</u>

*For subcontract detail see Appendix A.

	<u>Budget</u> 5/17/83- 6/30/84	<u>Expended</u> To Date 6/30/84	<u>Expended</u> This Period 7/1/84-9/30/84
<u>International Programs</u>			
<u>Pre-Introduction of Copper-T IUD</u>			
Salaries and Benefits	\$ 35,066.00	\$ 36,950.00	\$ -
Contraceptive Supplies	15,000.00	-	-
Communications and Supplies	1,500.00	1,303.97	-
Travel	5,000.00	2,489.00	-
Meetings	434.00	647.38	-
Legal Fees	18,000.00	29,255.16	-
<u>Total Direct Costs</u>	<u>75,000.00</u>	<u>70,645.51</u>	<u>-</u>
<u>Indirect Cost @ 38.26% (\$9,300.59)</u>	<u>3,558.41</u>	<u>1,892.38</u>	<u>-</u>
<u>Indirect Cost @ 33.28% (\$65,699.41)</u>	<u>21,864.76</u>	<u>21,864.76</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>25,423.17</u>	<u>23,757.14</u>	<u>-</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 100,423.17</u>	<u>\$ 94,402.65</u>	<u>\$ -</u>
	<u>9/15/83- 12/31/83</u>	<u>12/31/83</u>	<u>7/1/84-9/30/84</u>
<u>Norplant Seminar</u>			
Travel and Per Diem	\$ 12,436.92	\$ 12,436.92	\$ -
Equipment Rental	1,133.00	1,133.00	-
Seminar Luncheon	871.00	871.00	-
Translation	570.00	570.00	-
Other Direct Costs	3,123.60	3,123.60	-
<u>Total Direct Costs</u>	<u>18,134.52</u>	<u>18,134.52</u>	<u>-</u>
<u>Indirect Cost @ 33.28% (\$20,000.00)</u>	<u>6,035.17</u>	<u>6,035.17</u>	<u>-</u>
<u>Total Direct and Indirect Cost</u>	<u>\$ 24,169.69</u>	<u>\$ 24,169.69</u>	<u>\$ -</u>
	<u>7/ 1/83- 6/30/84</u>	<u>6/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Management Consultant</u>			
Forrest Greenslade	\$ 6,241.70	\$ 6,241.70	\$ -
<u>Indirect Cost @ 38.26% (\$4,182.66)</u>	<u>1,004.08</u>	<u>1,004.08</u>	<u>-</u>
<u>Indirect Cost @ 33.28% (\$3,617.34)</u>	<u>1,203.85</u>	<u>1,203.85</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>2,207.93</u>	<u>2,207.93</u>	<u>-</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 8,449.63</u>	<u>\$ 8,449.63</u>	<u>\$ -</u>

Cont's on next page

	<u>Budget</u> <u>5/17/83-</u> <u>12/31/84(1)</u>	<u>Expended</u> <u>To Date</u> <u>9/30/84</u>	<u>Expended</u> <u>This Period</u> <u>7/1/84-9/30/84</u>
<u>Design, Implementation, Evaluation of</u>			
<u>Family Planning Projects in Sub-Saharan</u>			
<u>Africa</u>			
Salaries and Benefits	\$ 51,377.00	\$ 38,469.78	\$ 4,404.16
Consultants	11,938.00	2,760.00	-
Travel and Per Diem	38,470.00	22,760.25	5,198.64
Educational Materials	15,267.00	836.50	89.40
Communication	1,259.00	737.83	10.22
Participant Training	16,600.00	9,212.87	9,212.87
<u>Total Direct Costs</u>	<u>134,911.00</u>	<u>74,777.23</u>	<u>18,915.29</u>
<u>Indirect Cost @ 38.26% (\$105,619.90)</u>	<u>33,508.07</u>	<u>17,403.00</u>	<u>7,236.99</u>
<u>Indirect Cost @ 33.28% (\$26,531.10)</u>	<u>8,829.55</u>	<u>8,829.55</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>42,337.62</u>	<u>26,232.55</u>	<u>7,236.99</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 177,248.62</u>	<u>\$101,009.78</u>	<u>\$ 26,152.28</u>
	<u>4/ 1/84-</u> <u>3/31/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Project on Copper-T IUD Training and</u>			
<u>Evaluation in Brazil</u>			
Salaries and Benefits	\$ 7,758.00	\$ 4,704.07	\$ 2,572.42
Allowances	2,500.00	414.97	254.78
Office Expenses	3,000.00	955.81	520.85
In-Country Travel	1,500.00	26.29	-
Sub-Award - CEMICAMP	53,028.00	10,000.00	-
<u>Total Direct Costs</u>	<u>67,786.00</u>	<u>16,101.14</u>	<u>3,348.05</u>
<u>Indirect Cost @ 38.26%</u>	<u>25,934.92</u>	<u>6,160.29</u>	<u>1,280.96</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 93,720.92</u>	<u>\$ 22,261.43</u>	<u>\$ 4,629.01</u>
	<u>3/ 1/84-</u> <u>7/31/85</u>	<u>9/30/84</u>	<u>7/1/84-9/30/84</u>
<u>Mexican Social Security Institute</u>			
Salaries and Benefits	\$ 9,096.00	\$ 2,472.39	\$ 2,472.39
Travel	2,400.00	1,032.83	665.50
Per Diem	1,932.00	-	-
Sub-Award-IMSS	66,136.00	27,379.00	7,379.00
<u>Total Direct Costs</u>	<u>79,564.00</u>	<u>30,884.22</u>	<u>10,516.89</u>
<u>Indirect Cost @ 38.26%</u>	<u>30,441.19</u>	<u>11,816.30</u>	<u>4,023.67</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 110,005.19</u>	<u>\$ 42,700.52</u>	<u>\$ 14,540.56</u>

Cont'd on next page

	Budget 5/16/84- 6/30/85	Expended To Date 9/30/84	Expended This Period 7/1/84-9/30/84
<u>International Centre for Diarrhoeal Disease Research, Bangladesh</u>			
Salaries and Benefits	\$ 57,053.76	\$ 18,719.60	\$ 12,479.73
Workmen's Compensation Insurance	1,383.24	-	-
Housing	14,520.00	2,338.63	2,338.63
Education	3,500.00	3,500.00	3,500.00
Storage	1,350.00	-	-
Night Watchman	450.00	122.12	122.12
Travel	6,400.00	2,814.64	2,814.64
Home Leave	8,800.00	-	-
Automobile	3,938.00	282.91	282.91
Relocation Costs	18,062.00	485.50	485.50
Communication	945.00	504.27	504.27
Miscellaneous Expenses	1,100.00	440.72	440.72
Subcontracts to ICDDR	46,392.00	11,598.00	11,598.00
<u>Total Direct Costs</u>	163,894.00	40,806.39	34,566.52
<u>Indirect Cost @ 38.26%</u>	62,705.84	15,612.52	13,225.15
<u>Total Direct and Indirect Costs</u>	\$ 226,599.84	\$ 56,418.91	\$ 47,791.67
<u>Pre-Introduction Evaluation of Norplant® Contraceptive Subdermal Implants</u>			
	4/ 1/84- 3/31/85	9/30/84	7/1/84-9/30/84
Salaries and Benefits	\$ 77,139.00	\$ 38,569.50	\$29,691.87
Allowances	10,962.00	4,844.71	2,851.46
Consultants	20,723.00	-	-
Production Costs	20,000.00	-	-
Travel and Transportation	7,988.00	2,773.08	2,548.08
Subcontract-Mahidol University	9,250.00	3,500.00	-
Subcontract-CONAPOFA	62,906.00	-	-
Subcontract-PROFAMILIA	24,863.00	-	-
Subcontract-ONPEP	20,000.00	-	-
Subcontract-CDP	20,386.00	-	-
Subcontract-APROFE	24,783.00	-	-
<u>Total Direct Costs</u>	299,000.00	49,687.29	35,091.41
<u>Indirect Cost @ 38.26%</u>	106,468.78	19,010.35	13,425.97
<u>Total Direct and Indirect Costs</u>	\$ 405,468.78	\$ 68,697.64	\$48,517.38
<u>Pre-Introduction of Norplant® Contraceptive Subdermal Implants</u>			
	1/ 1/84- 6/30/84	6/30/84	7/1/84-9/30/84
Salaries and Benefits	\$ 65,167.00	\$ 70,270.01	\$ -
Allowances	8,685.00	5,541.13	-
Consultants	6,005.00	3,755.00	1,800.00
Audio Visual Materials	200.00	114.14	-
Local Meetings	250.00	273.58	-
Communications	2,550.00	2,903.14	-
<u>Total Direct Costs</u>	82,857.00	82,857.00	1,800.00
<u>Indirect Cost @ 38.26%</u>	29,403.58	30,264.43	-
<u>Indirect Cost Chargeable to P.C.</u>	-	(860.85)	(860.85)
<u>Total Direct and Indirect Costs</u>	\$ 112,260.58	\$112,260.58	\$ 939.15

	Budget 1/ 1/84- 12/31/84	Expended To Date 9/30/84	Expended This Period 7/1/84-9/30/84
<u>Expanding Health Service Coverage in Columbia</u>			
Salaries and Benefits	\$ 10,064.00	\$ 8,700.88	\$ 2,871.81
Allowances	4,130.00	1,404.59	1,067.50
Subcontract	72,995.00	25,000.00	-
<u>Total Direct Cost</u>	87,189.00	35,105.47	3,939.31
<u>Total Indirect Cost @ 38.26%</u>	33,358.51	13,431.35	1,507.18
<u>Total Direct and Indirect Costs</u>	<u>\$120,547.51</u>	<u>\$ 48,536.82</u>	<u>\$ 5,446.49</u>
<u>Total Obligated Direct Cost</u>			
<u>International Programs</u>	\$1,014,577.22	\$ 425,240.47	\$108,177.47
<u>Total Obligated Indirect Costs</u>			
<u>International Programs</u>	364,316.71	154,528.02	40,700.01
<u>Total Obligated Direct and Indirect Costs - International Programs</u>	<u>\$1,378,893.93</u>	579,768.49	148,877.48
<u>Chargeable to Population Council</u>		(860.85)	(860.85)
<u>Chargeable to AID</u>		<u>\$ 578,907.64</u>	<u>\$148,016.63</u>
	5/16/83- 4/30/84	4/30/84	7/1/84-9/30/84
<u>Management Support Services-Bogota Office</u>			
Salaries and Benefits	\$ 10,000.00	\$ 12,183.15	\$ -
Travel	7,000.00	687.23	-
Expendable Supplies	2,000.00	268.58	-
Rent	6,000.00	5,625.00	-
Communication	2,000.00	1,945.94	-
Other Direct Costs	3,000.00	2,478.55	-
<u>Total Direct Costs</u>	30,000.00	23,188.45	-
<u>Indirect Cost @ 12%</u>	1,952.87	1,952.87	-
<u>Indirect Cost @ 11.5%</u>	1,578.50	795.17	-
<u>Total Indirect Costs</u>	3,531.37	2,748.04	-
<u>Total Direct and Indirect Costs</u>	<u>\$ 33,531.37</u>	<u>\$ 25,936.49</u>	<u>\$ -</u>
	5/ 1/84- 4/30/85	9/30/84	7/1/84-9/30/84
<u>Management Support Services-Bogota Office</u>			
Salaries and Benefits	\$ 12,000.00	\$ 3,153.16	\$ 1,371.09
Travel	4,000.00	579.95	214.14
Expendable Supplies	2,000.00	256.36	176.26
Rent	6,000.00	1,800.00	2,250.00*
Communication	3,000.00	664.60	616.20
Other Direct Costs	3,000.00	383.90	707.39**
<u>Total Direct Costs</u>	30,000.00	6,837.97	5,335.08
<u>Indirect Cost @ 11.5%</u>	3,450.00	786.37	613.53
<u>Total Direct and Indirect Costs</u>	<u>\$ 33,450.00</u>	<u>\$ 7,624.34</u>	<u>\$ 5,948.61</u>

	<u>Budget</u> 5/16/83- 4/30/85	<u>Expended</u> To Date 9/30/84	<u>Expended</u> This Period 7/1/84-9/30/84
<u>Total Obligated Direct Costs-Management</u> <u>Support Service-Bogota Office</u>	\$ 60,000.00	\$ 30,026.42	\$ 5,335.08
<u>Total Obligated Indirect Costs-Management</u> <u>Support Services-Bogota Office</u>	6,981.37	3,534.41	613.53
<u>Total Obligated Direct and Indirect Costs</u> <u>Management and Support Services-Bogota</u> <u>Office</u>	<u>\$ 66,981.37</u>	<u>\$ 33,560.83</u>	<u>\$ 5,948.61</u>
<u>TOTAL DIRECT COSTS ALL DIVISIONS</u>	\$3,367,266.22	\$1,558,323.15	\$415,135.43
<u>TOTAL INDIRECT COSTS ALL DIVISIONS</u>	<u>1,331,695.22</u>	<u>596,924.58</u>	<u>173,545.03</u>
<u>TOTAL DIRECT AND INDIRECT COSTS</u> <u>ALL DIVISIONS</u>	<u>\$4,698,961.44</u>	2,155,247.73	588,680.46
<u>Chargeable to Population Council</u>		(860.85)	(860.85)
<u>Chargeable to AID</u>		<u>\$2,154,386.88</u>	<u>\$587,819.61</u>

* Prior to 7/1/84 this budget line had a credit balance of (\$450.00).

** Prior to 7/1/84 this budget line had a credit balance of (\$323.49).

The undersigned hereby certifies: (A) That payment of the sum claimed under the cited agreement is proper and due and that appropriate refund to AID will be made promptly upon request in the event of disallowance of costs not reimbursable under the terms of the agreement, (B) That information on the fiscal report is correct and such detailed supporting information as AID may reasonably require will be furnished promptly to AID on request at the Contractor's home office or base office as appropriate and (C) That all requirements called for by the agreement to the date of this certification have been met.


 BY: _____
 George A. Babb

Title: Assistant Treasurer
and Comptroller

Date: January 28, 1985

Contraceptive Development Program increased by \$788,000.00 Direct Cost per Amendment No. 3, dated 3/1/84.

New Provisional Indirect Cost Rates per Agreement dated 9/10/84, signed by J. Derry effective 1/1/84 (see attachment B).

The Population CouncilCOOPERATIVE AGREEMENT No. AID/DPF-3005-A-00-3003-00
STATEMENT OF EXPENDITURESFor the Period July 1, 1984 to September 30, 1984Center for Biomedical Research
Contraceptive Development Program Subcontracts

	<u>Budget</u> 5/17/83- 2/28/85	<u>Expended</u> To Date 9/30/84	<u>Expended</u> This Period 7/1/84-9/30/84
<u>Subdermal Implants - Subcontracts</u>			
CB83.53A/ICCR-Professional Staff Association of the LAC/USC Medical Center	\$ 42,134.00	\$ 42,134.00	\$ -
CB83.61A/ICCR-Professional Staff Association of the LAC/USC Medical Center	14,000.00	14,000.00	-
CB84.01A/ICCR-Centro Nacional de la Familia	31,000.00	15,500.00	-
CB84.30A/ICCR-University of Helsinki, Finland	15,000.00	7,500.00	7,500.00
CB84.32A/ICCR-Professional Staff Association of the LAC/USC Medical Center	60,081.00	-	-
<u>Total</u>	<u>162,215.00</u>	<u>79,134.00</u>	<u>7,500.00</u>
<u>Contraceptive Rings - Subcontracts</u>			
CB83.54A/ICCR-The George Washington University	39,232.00	39,232.00	19,616.00
CB84.02A/ICCR-Emory University School of Medicine	72,689.00	24,231.00	-
CB84.20A/ICCR-The George Washington University	29,625.00	14,812.50	14,812.50
CB84.25A/ICCR-The George Washington University	48,044.00	-	-
<u>Total</u>	<u>189,590.00</u>	<u>78,275.50</u>	<u>34,428.50</u>
<u>Levonorgestrel IUD-Subcontracts</u>			
CB83.66A/ICCR-Professional Staff Association of the LAC/USC Medical Center	47,520.00	23,760.00	-
CB84.09A/ICCR-PROFAMILIA, Dominican Republic	23,616.00	12,638.00	-
CB84.14A/ICCR-Technologia Institute, Brazil	18,000.00	9,000.00	-
CB84.18A/ICCR-Argus Research Labs., Inc.	26,306.00	26,306.00	13,153.00
CB84.46A/ICCR-Centro Nacional de la Familia	21,000.00	-	-
<u>Total</u>	<u>136,442.00</u>	<u>71,704.00</u>	<u>13,153.00</u>
<u>LHRH Analogs- Subcontracts</u>			
CB83.72A/ICCR-Professional Staff Association of the LAC/USC Medical Center	13,772.00	13,772.00	-
CB84.07A/ICCR-Urologische Abteilung, Austria	8,000.00	8,000.00	-
<u>Total</u>	<u>21,772.00</u>	<u>21,772.00</u>	<u>-</u>

Cont'd on next page

47

The Population Council

COOPERATIVE AGREEMENT No. AID/DPE-3005-A-00-3003-00
STATEMENT OF EXPENDITURES

For the Period July 1, 1984 to September 30, 1984

Center for Biomedical Research
Contraceptive Development Program Subcontracts

	<u>Budget</u> <u>5/17/83-</u> <u>2/28/85</u>	<u>Expended</u> <u>To Date</u> <u>9/30/84</u>	<u>Expended</u> <u>This Period</u> <u>7/1/84-9/30/84</u>
<u>Inhibin - Subcontracts</u>			
CB83.37A/ICCR-Salk Institute, California	83,297.00	83,297.00	-
CB83.79A/ICCR-Salk Institute, California	106,666.00	106,666.00	-
CB84.10A/ICCR-Florida Institute of Technology	30,340.00	15,170.00	-
CB84.27A/ICCR-Salk Institute, California	<u>257,000.00</u>	<u>128,539.00</u>	<u>128,539.00</u>
<u>Total</u>	<u>477,303.00</u>	<u>333,672.00</u>	<u>128,539.00</u>
<u>Gonadotropin-Surge-Inhibiting Factor-Subcontracts</u>			
CB84.35A/ICCR-Eastern Virginia Medical School	78,662.00	-	-
CB84.43A/ICCR-Eastern Virginia Medical School	<u>150,163.00</u>	<u>-</u>	<u>-</u>
	<u>228,825.00</u>	<u>-</u>	<u>-</u>
<u>Total Subcontracts-Contraceptive</u> <u>Development Program</u>	<u>\$1,215,147.00</u>	<u>\$584,557.50</u>	<u>\$183,620.50</u>

48

The Population Council

Fiscal Report No. 6
Page 1 of 8

COOPERATIVE AGREEMENT No. AID/DPE-3005-A-00-3003-00
STATEMENT OF EXPENDITURES

For the Period October 1, 1984 to December 31, 1984

	<u>Budget</u> <u>5/17/83-</u> <u>5/16/84</u>	<u>Expended</u> <u>To Date</u> <u>5/16/84</u>	<u>Expended</u> <u>This Period</u> <u>10/1/84-12/31/84</u>
<u>In-House Projects</u>			
<u>Center for Biomedical Research</u>			
<u>Contraceptive Ring (1)</u>			
Salaries and Benefits	\$ 77,988.00	\$ 77,988.00	\$ -
Rabbits and Animal Maintenance	2,000.00	2,000.00	-
Laboratory Supplies	1,000.00	1,000.00	-
Awards and Subcontracts*	111,921.00	63,463.00	-
Technology Transfer	<u>8,896.00</u>	<u>8,896.00</u>	<u>-</u>
<u>Total Direct Costs</u>	<u>201,805.00</u>	<u>153,347.00</u>	<u>-</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Contraceptive Ring (2)</u>			
Salaries and Benefits	95,193.00	81,127.55	23,798.25
Awards and Subcontracts*	<u>92,669.00</u>	<u>38,834.50</u>	<u>24,022.00</u>
<u>Total Direct Costs</u>	<u>187,862.00</u>	<u>119,962.05</u>	<u>47,820.25</u>
<u>Total Direct Cost Contraceptive Rings</u>	<u>389,667.00</u>	<u>273,309.05</u>	<u>47,820.25</u>
<u>Indirect Cost @ 43.84%</u>	<u>162,401.98</u>	<u>111,390.66</u>	<u>20,964.40</u>
<u>Total Direct and Indirect Costs</u>	<u>\$552,068.98</u>	<u>\$384,699.71</u>	<u>\$ 68,784.65</u>
	<u>5/17/83-</u> <u>5/16/84</u>	<u>5/16/84</u>	<u>10/1/84-12/31/84</u>
<u>Levonorgestrel IUD (1)</u>			
Salaries and Benefits	\$ 31,280.00	\$ 31,280.00	\$ -
Laboratory Supplies	1,200.00	1,200.00	-
Awards and Subcontracts*	<u>47,520.00</u>	<u>47,520.00</u>	<u>23,760.00</u>
<u>Total Direct Costs</u>	<u>80,000.00</u>	<u>80,000.00</u>	<u>23,760.00</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Levonorgestrel IUD (2)</u>			
Awards and Subcontracts*	\$ 88,922.00	\$ 58,922.00	\$ 10,978.00
<u>Total Direct Costs</u>	<u>88,922.00</u>	<u>58,922.00</u>	<u>10,978.00</u>
<u>Total Direct Cost Levonorgestrel</u>	<u>168,922.00</u>	<u>130,922.00</u>	<u>34,738.00</u>
<u>Indirect Cost @ 43.84%</u>	<u>68,882.10</u>	<u>55,730.10</u>	<u>15,229.14</u>
<u>Total Direct and Indirect Costs</u>	<u>\$237,804.10</u>	<u>\$194,652.10</u>	<u>\$ 49,967.14</u>

*For subcontract detail see Appendix A

Cont'd on next page..

31

	<u>Budget</u> <u>5/17/83-</u> <u>5/16/84(1)</u>	<u>Expended</u> <u>To Date</u> <u>5/16/84</u>	<u>Expended</u> <u>This Period</u> <u>10/1/84-12/31/84</u>
<u>Subdermal Implants (1)</u>			
Salaries and Benefits	\$121,224.00	\$121,224.00	\$ -
Laboratory Supplies	818.00	818.00	-
Awards and Subcontracts*	87,134.00	71,634.00	-
<u>Total Direct Costs</u>	<u>209,176.00</u>	<u>193,676.00</u>	<u>-</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Subdermal Implants (2)</u>			
Salaries and Benefits	138,367.00	115,882.35	34,659.25
Awards and Contracts*	347,147.00	37,540.50	30,040.50
<u>Total Direct Costs</u>	<u>485,514.00</u>	<u>153,422.85</u>	<u>64,699.75</u>
<u>Total Direct Cost Subdermal Implants</u>	<u>694,690.00</u>	<u>347,098.85</u>	<u>64,699.75</u>
<u>Indirect Cost @ 43.84%</u>	<u>290,115.79</u>	<u>137,731.83</u>	<u>28,364.37</u>
<u>Total Direct and Indirect Costs</u>	<u>\$984,805.79</u>	<u>\$484,830.68</u>	<u>\$ 93,064.12</u>
	<u>5/17/83-</u> <u>5/16/84</u>	<u>5/16/84</u>	<u>10/1/84-12/31/84</u>
<u>LHRH Analogs (1)</u>			
Salaries and Benefits	\$ 43,970.00	\$ 43,970.00	\$ -
Awards and Subcontracts*	21,772.00	21,772.00	-
<u>Total Direct Costs</u>	<u>65,742.00</u>	<u>65,742.00</u>	<u>-</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>LHRH Analogs (2)</u>			
Salaries and Benefits	34,414.00	30,318.20	8,603.50
Laboratory Supplies	35,867.00	24,815.13	9,656.83
Awards and Subcontracts*	16,230.00	-	-
<u>Total Direct Costs</u>	<u>86,511.00</u>	<u>55,133.33</u>	<u>18,260.33</u>
<u>Total Direct Cost LHRH Analogs</u>	<u>152,253.00</u>	<u>120,875.33</u>	<u>18,260.33</u>
<u>Indirect Cost @ 43.84%</u>	<u>63,915.72</u>	<u>50,159.74</u>	<u>8,005.33</u>
<u>Total Direct and Indirect Costs</u>	<u>\$216,168.72</u>	<u>\$171,035.07</u>	<u>\$ 26,265.66</u>
	<u>5/16/83-</u> <u>5/15/84</u>	<u>5/15/84</u>	<u>10/1/84-12/31/84</u>
<u>Food and Drug Administration Filing Assistant</u>			
Consultant Fees	\$ 11,000.00	\$ 11,000.00	\$ -
<u>No Indirect Cost</u>	<u></u>	<u></u>	<u></u>

* For subcontract details see Appendix A.

	<u>Budget</u> <u>5/16/83-</u> <u>5/15/84</u>	<u>Expended</u> <u>To Date</u> <u>5/15/84</u>	<u>Expended</u> <u>This Period</u> <u>10/1/84-12/31/84</u>
<u>Inhibin (1)</u>			
Salaries and Benefits	\$ 7,314.00	\$ 7,314.00	\$ -
Laboratory Supplies	6,000.00	6,000.00	-
Awards and Subcontracts*	189,963.00	189,963.00	-
<u>Total Direct Costs</u>	<u>203,277.00</u>	<u>203,277.00</u>	<u>-</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Inhibin (2)</u>			
Awards and Subcontracts*	287,400.00	223,144.00	79,435.00
<u>Total Direct Costs</u>	<u>287,400.00</u>	<u>223,144.00</u>	<u>79,435.00</u>
<u>Total Direct Cost Inhibin</u>	<u>490,677.00</u>	<u>426,421.00</u>	<u>79,435.00</u>
<u>Indirect Cost @ 43.84%</u>	<u>206,087.12</u>	<u>177,917.29</u>	<u>34,824.30</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 696,764.12</u>	<u>\$ 604,338.29</u>	<u>\$114,259.30</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Gonadotropin-Surge-Inhibiting Factor</u>			
Salaries and Benefits	\$ 5,865.00	\$ 3,180.00	\$ 954.00
HPLC Columns	5,000.00	-	-
Laboratory Supplies	7,500.00	9,224.50	5,000.00
Awards and Subcontracts*	233,635.00	27,824.00	27,824.00
<u>Total Direct Costs</u>	<u>252,000.00</u>	<u>40,228.50</u>	<u>33,778.00</u>
<u>Indirect Cost @ 43.84%</u>	<u>110,476.80</u>	<u>17,636.18</u>	<u>14,808.28</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 362,476.80</u>	<u>\$ 57,864.68</u>	<u>\$ 48,586.28</u>
	<u>3/ 1/84-</u> <u>2/28/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Tolnidamine</u>			
Salaries and Benefits	\$ 54,270.00	\$ 15,658.00	\$ 651.40
Animal Maintenance	79,210.00	18,223.96	9,297.70
<u>Total Direct Costs</u>	<u>133,480.00</u>	<u>33,881.96</u>	<u>9,949.10</u>
<u>Indirect Cost @ 43.84%</u>	<u>58,517.63</u>	<u>14,853.86</u>	<u>4,361.69</u>
<u>Total Direct and Indirect Costs</u>	<u>191,997.63</u>	<u>48,735.82</u>	<u>14,310.79</u>
<u>Total Direct Costs Costs-Center</u> <u>for Biomedical Research</u>	<u>2,292,689.00</u>	<u>1,391,736.69</u>	<u>288,680.43</u>
<u>Total Indirect Costs-Center</u> <u>for Biomedical Research</u>	<u>960,397.14</u>	<u>565,419.66</u>	<u>126,557.51</u>
<u>Total Direct and Indirect Costs-</u> <u>Center for Biomedical Research</u>	<u>\$3,253,086.14</u>	<u>\$1,957,156.35</u>	<u>\$415,237.94</u>

*For subcontract detail see Appendix A.

Cont's on next page.. 61

	<u>Budget</u> 5/17/83- 6/30/84	<u>Expended</u> To Date 6/30/84	<u>Expended</u> This Period 10/1/84-12/31/84
<u>International Programs</u>			
<u>Pre-Introduction of Copper-T IUD</u>			
Salaries and Benefits	\$ 35,066.00	\$ 36,950.00	\$ -
Contraceptive Supplies	15,000.00	395.07	395.07
Communications and Supplies	1,500.00	1,303.97	-
Travel	5,000.00	2,489.00	-
Meetings	434.00	647.38	-
Legal Fees	18,000.00	30,795.14	1,539.98
<u>Total Direct Costs</u>	<u>75,000.00</u>	<u>72,580.56</u>	<u>1,935.05</u>
<u>Indirect Cost @ 38.26% (\$9,300.59)</u>	<u>3,558.41</u>	<u>2,632.73</u>	<u>740.35</u>
<u>Indirect Cost @ 33.28% (\$65,699.41)</u>	<u>21,864.76</u>	<u>21,864.76</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>25,423.17</u>	<u>24,497.49</u>	<u>740.35</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 100,423.17</u>	<u>\$ 97,078.05</u>	<u>\$ 2,675.40</u>
	<u>9/15/83-</u> <u>12/31/83</u>	<u>12/31/83</u>	<u>10/1/84-12/31/84</u>
<u>Norplant Seminar</u>			
Travel and Per Diem	\$ 12,436.92	\$ 12,436.92	\$ -
Equipment Rental	1,133.00	1,133.00	-
Seminar Luncheon	871.00	871.00	-
Translation	570.00	570.00	-
Other Direct Costs	3,123.60	3,123.60	-
<u>Total Direct Costs</u>	<u>18,134.52</u>	<u>18,134.52</u>	<u>-</u>
<u>Indirect Cost @ 33.28% (\$20,000.00)</u>	<u>6,035.17</u>	<u>6,035.17</u>	<u>-</u>
<u>Total Direct and Indirect Cost</u>	<u>\$ 24,169.69</u>	<u>\$ 24,169.69</u>	<u>\$ -</u>
	<u>7/ 1/83-</u> <u>6/30/84</u>	<u>6/30/84</u>	<u>10/1/84-12/31/84</u>
<u>Management Consultant</u>			
Forrest Greenslade	\$ 6,241.70	\$ 6,241.70	\$ -
<u>Indirect Cost @ 38.26% (\$4,182.66)</u>	<u>1,004.08</u>	<u>1,004.08</u>	<u>-</u>
<u>Indirect Cost @ 33.28% (\$3,617.34)</u>	<u>1,203.85</u>	<u>1,203.85</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>2,207.93</u>	<u>2,207.93</u>	<u>-</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 8,449.63</u>	<u>\$ 8,449.63</u>	<u>\$ -</u>

Cont's on next page

97

	<u>Budget</u> 5/17/83- 12/31/84(1)	<u>Expended</u> To Date 12/31/84	<u>Expended</u> This Period 10/1/84-12/31/84
<u>Design, Implementation, Evaluation of</u> <u>Family Planning Projects in Sub-Saharan</u> <u>Africa</u>			
Salaries and Benefits	\$ 51,377.00	\$ 50,126.21	\$ 11,656.43
Consultants	11,938.00	2,760.00	-
Travel and Per Diem	38,470.00	27,412.98	4,652.73
Educational Materials	15,267.00	1,283.38	446.88
Communication	1,259.00	962.42	224.59
Participant Training	16,600.00	10,798.00	1,585.13
<u>Total Direct Costs</u>	<u>134,911.00</u>	<u>93,342.99</u>	<u>18,565.76</u>
<u>Indirect Cost @ 38.26% (\$105,619.90)</u>	<u>33,508.07</u>	<u>24,506.26</u>	<u>7,103.26</u>
<u>Indirect Cost @ 33.28% (\$26,531.10)</u>	<u>8,829.55</u>	<u>8,829.55</u>	<u>-</u>
<u>Total Indirect Costs</u>	<u>42,337.62</u>	<u>33,335.81</u>	<u>7,103.26</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 177,248.62</u>	<u>\$126,678.80</u>	<u>\$ 25,669.02</u>
	<u>4/ 1/84-</u> <u>3/31/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Project on Copper-T IUD Training and</u> <u>Evaluation in Brazil</u>			
Salaries and Benefits	\$ 7,758.00	\$ 7,788.23	\$ 3,084.16
Allowances	2,500.00	998.63	583.66
Office Expenses	3,000.00	1,966.36	1,010.55
In-Country Travel	1,500.00	201.36	175.07
Sub-Award - CEMICAMP	53,028.00	15,000.00	5,000.00
<u>Total Direct Costs</u>	<u>67,786.00</u>	<u>24,954.58</u>	<u>9,853.44</u>
<u>Indirect Cost @ 38.26%</u>	<u>25,934.92</u>	<u>9,930.22</u>	<u>3,769.93</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 93,720.92</u>	<u>\$ 35,884.80</u>	<u>\$ 13,623.37</u>
	<u>3/ 1/84-</u> <u>7/31/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
<u>Mexican Social Security Institute</u>			
Salaries and Benefits	\$ 9,096.00	\$ 2,533.39	\$ 61.00
Travel	2,400.00	1,537.60	504.77
Per Diem	1,932.00	-	-
Sub-Award-IMSS	66,136.00	56,901.48	29,522.48
<u>Total Direct Costs</u>	<u>79,564.00</u>	<u>60,972.47</u>	<u>30,068.25</u>
<u>Indirect Cost @ 38.26%</u>	<u>30,441.19</u>	<u>23,328.06</u>	<u>11,511.76</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 110,005.19</u>	<u>\$ 84,300.53</u>	<u>\$ 41,600.01</u>

Cont'd on next page

93


<u>International Centre for Diarrhoeal Disease Research, Bangladesh</u>	<u>Budget 5/16/84- 6/30/85</u>	<u>Expended To Date 12/31/84</u>	<u>Expended This Period 10/1/84-12/31/84</u>
Salaries and Benefits	\$ 57,053.76	\$ 32,397.21	\$ 13,677.61
Housing	14,520.00	3,480.82	1,142.19
Education	3,500.00	3,500.00	-
Storage	1,350.00	-	-
Night Watchman	450.00	216.17	94.05
Travel	6,400.00	3,485.22	670.58
Home Leave	8,800.00	-	-
Automobile	3,938.00	601.98	319.07
Relocation Costs	18,062.00	776.80	291.30
Communication	945.00	654.79	150.52
Miscellaneous Expenses	2,483.24	502.03	61.31
Subcontracts to ICDDR	46,392.00	23,196.00	11,598.00
<u>Total Direct Costs</u>	<u>163,894.00</u>	<u>68,811.02</u>	<u>28,004.63</u>
<u>Indirect Cost @ 38.26%</u>	<u>62,705.84</u>	<u>26,327.09</u>	<u>10,714.57</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 226,599.84</u>	<u>\$ 95,138.11</u>	<u>\$ 38,719.20</u>
<u>Pre-Introduction Evaluation of Norplant[®] Contraceptive Subdermal Implants</u>	<u>4/ 1/84- 3/31/85</u>	<u>12/31/84</u>	<u>10/1/84-12/31/84</u>
Salaries and Benefits	\$ 77,139.00	\$ 57,584.25	\$19,014.75
Allowances	10,962.00	5,946.39	1,101.68
Consultants	21,473.00	10,531.32	10,531.32
Travel and Transportation	10,249.00	6,309.45	3,536.37
Subcontract-Mahidol University	9,250.00	7,000.00	3,500.00
Subcontract-CONAPOFA	62,906.00	10,000.00	10,000.00
Subcontract-CCRP	34,033.00	-	-
Subcontract-CEMICAMP	50,000.00	-	-
Subcontract-CDP	16,755.00	-	-
Subcontract-APROFE	24,783.00	4,000.00	4,000.00
<u>Total Direct Costs</u>	<u>317,550.00</u>	<u>101,371.41</u>	<u>51,684.12</u>
<u>Indirect Cost @ 38.26%</u>	<u>106,468.78</u>	<u>34,755.40</u>	<u>15,745.06</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 424,018.78</u>	<u>\$136,126.81</u>	<u>\$67,429.18</u>
<u>Pre-Introduction of Norplant[®] Contraceptive Subdermal Implants</u>	<u>1/ 1/84- 6/30/84</u>	<u>6/30/84</u>	<u>10/1/84-12/31/84</u>
Salaries and Benefits	\$ 65,167.00	\$ 70,270.01	\$ -
Allowances	8,685.00	5,541.13	-
Consultants	6,005.00	3,755.00	-
Audio Visual Materials	200.00	114.14	-
Local Meetings	250.00	273.58	-
Communications	2,550.00	2,903.14	-
<u>Total Direct Costs</u>	<u>82,857.00</u>	<u>82,857.00</u>	<u>-</u>
<u>Indirect Cost @ 38.26%</u>	<u>29,403.58</u>	<u>30,264.43</u>	<u>-</u>
<u>Indirect Cost Chargeable to P.C.</u>	<u>-</u>	<u>860.85</u>	<u>-</u>
<u>Total Direct and Indirect Costs</u>	<u>\$ 112,260.58</u>	<u>\$113,982.28</u>	<u>\$ -</u>

94

	Budget 1/ 1/84- 12/31/84	Expended to Date 12/31/84	Expended This Period 10/1/84-12/31/84
<u>Expanding Health Service Coverage in Columbia</u>			
Salaries and Benefits	\$ 10,064.00	\$ 11,511.78	\$ 2,810.90
Allowances	4,130.00	2,715.20	1,310.61
Subcontract	72,995.00	57,392.00	32,392.00
<u>Total Direct Cost</u>	87,189.00	71,618.98	36,513.51
<u>Total Indirect Cost @ 38.26%</u>	33,358.51	27,401.42	13,970.07
<u>Total Direct and Indirect Costs</u>	<u>\$120,547.51</u>	<u>\$ 99,020.40</u>	<u>\$ 50,483.58</u>
<u>Sub-wards International Programs</u>			
184.24A Academia Mexicana	\$ 5,700.00	\$ 5,700.00	\$ 5,700.00
<u>Total Direct Cost</u>	5,700.00	5,700.00	5,700.00
<u>Total Indirect Cost @ 38.26%</u>	2,180.82	2,180.82	2,180.82
<u>Total Direct and Indirect Costs</u>	<u>\$ 7,880.82</u>	<u>\$ 7,880.82</u>	<u>\$ 7,880.82</u>
<u>Total Obligated Direct Cost International Programs</u>	\$1,038,827.22	\$ 607,585.23	\$182,344.76
<u>Total Obligated Indirect Costs International Programs</u>	366,497.53	221,124.69	65,735.82
<u>Total Obligated Direct and Indirect Costs - International Programs</u>	<u>\$1,405,324.75</u>	828,709.92	248,080.58
<u>Chargeable to Population Council</u>		860.85	-
<u>Chargeable to AID</u>		<u>\$ 827,849.07</u>	<u>\$248,080.58</u>
<u>Management Support Services-Bogota Office</u>			
	5/16/83- 4/30/84	4/30/84	10/1/84-12/31/84
Salaries and Benefits	\$ 10,000.00	\$ 12,183.15	\$ -
Travel	7,000.00	687.23	-
Expendable Supplies	2,000.00	268.58	-
Rent	6,000.00	5,625.00	-
Communication	2,000.00	1,945.94	-
Other Direct Costs	3,000.00	2,478.55	-
<u>Total Direct Costs</u>	30,000.00	23,188.45	-
<u>Indirect Cost @ 12%</u>	1,952.87	1,952.87	-
<u>Indirect Cost @ 11.5%</u>	1,578.50	795.17	-
<u>Total Indirect Costs</u>	3,531.37	2,748.04	-
<u>Total Direct and Indirect Costs</u>	<u>\$ 33,531.37</u>	<u>\$ 25,936.49</u>	<u>\$ -</u>

	Budget 5/ 1/84 4/30/85	Expended To Date 12/31/84	Expended This Period 10/1/84-12/31/84
<u>Management Support Services-Bogota Office</u>			
Salaries and Benefits	\$ 12,000.00	\$ 6,769.91	\$ 3,616.75
Travel	4,000.00	1,470.30	890.35
Expendable Supplies	2,000.00	1,506.25	1,249.89
Rent	6,000.00	3,600.00	1,800.00
Communication	3,000.00	1,712.07	1,047.47
Other Direct Costs	3,000.00	684.81	300.91
<u>Total Direct Costs</u>	30,000.00	15,743.34	8,905.37
<u>Indirect Cost @ 11.5%</u>	5,028.50	1,810.48	1,024.11
<u>Total Direct and Indirect Costs</u>	\$ 35,028.50	\$ 17,553.82	\$ 9,929.48
<u>Total Obligated Direct Costs-Management Support Service-Bogota Office</u>	\$ 60,000.00	\$ 38,931.79	\$ 8,905.37
<u>Total Obligated Indirect Costs-Management Support Services-Bogota Office</u>	8,559.87	4,558.52	1,024.11
<u>Total Obligated Direct and Indirect Costs Management and Support Services-Bogota Office</u>	\$ 68,559.87	\$ 43,490.31	\$ 9,929.48
<u>TOTAL DIRECT COSTS ALL DIVISIONS</u>	\$3,391,516.22	\$2,038,253.71	\$479,930.56
<u>TOTAL INDIRECT COSTS ALL DIVISIONS</u>	1,335,454.54	791,102.87	193,317.44
<u>TOTAL DIRECT AND INDIRECT COSTS ALL DIVISIONS</u>	\$4,726,970.76	2,829,356.58	673,248.00
<u>Chargeable to Population Council</u>		860.85	-
<u>Chargeable to AID</u>		\$2,828,495.73	\$673,248.00

The undersigned hereby certifies: (A) That payment of the sum claimed under the cited agreement is proper and due and that appropriate refund to AID will be made promptly upon request in the event of disallowance of costs not reimbursable under the terms of the agreement, (B) That information on the fiscal report is correct and such detailed supporting information as AID may reasonably require will be furnished promptly to AID on request at the Contractor's home office or base office as appropriate and (C) That all requirements called for by the agreement to the date of this certification have been met.


 By: George A. Babb Title: Assistant Treasurer and Comptroller

Date: February 12, 1985

Contraceptive Development Program increased by \$788,000.00 Direct Cost per Amendment No. 3, dated 3/1/84.
New Provisional Indirect Cost Rates per Agreement dated 9/10/84, signed by J. Derry effective 1/1/84 (see attachment B).

96